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a  b  s  t  r  a  c  t
Cancer  is a key health  issue  across  the  world,  causing  substantial  patient  morbidity  and  mortality.  Patient
prognosis  is  tightly  linked  with  metastatic  dissemination  of  the disease  to  distant  sites,  with metastatic
diseases  accounting  for  a vast  percentage  of  cancer  patient  mortality.  While  advances  in  this  area  have
been made,  the  process  of cancer  metastasis  and  the  factors  governing  cancer  spread  and  establishment  at
secondary  locations  is  still  poorly  understood.  The  current  article  summarizes  recent  progress  in  this  area
of research,  both  in  the  understanding  of  the  underlying  biological  processes  and  in  the  therapeutic  strate-
gies  for  the  management  of  metastasis.  This review  lists  the disruption  of  E-cadherin  and  tight  junctions,
key  signaling  pathways,  including  urokinase  type  plasminogen  activator  (uPA),  phosphatidylinositol  3-
kinase/v-akt  murine  thymoma  viral  oncogene  (PI3K/AKT),  focal  adhesion  kinase  (FAK), -catenin/zinc
ﬁnger  E-box  binding  homeobox  1 (ZEB-1)  and  transforming  growth  factor beta  (TGF-),  together  with
inactivation  of  activator  protein-1  (AP-1)  and  suppression  of matrix  metalloproteinase-9  (MMP-9)  activ-
ity  as key  targets  and  the use  of  phytochemicals,  or natural  products,  such  as  those  from  Agaricus  blazei,
Albatrellus  conﬂuens,  Cordyceps  militaris,  Ganoderma  lucidum,  Poria  cocos  and  Silybum  marianum,  together
∗ Corresponding author at: Cardiff-Peking Cancer Institute and Cardiff-Capital Medical University Joint Centre for Biomedical Research, Cardiff University School of Medicine,
ardiff  University, Henry Wellcome Building, Heath Park, Cardiff CF14 4XN, United Kingdom. Tel.: +44 29 20687065.
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with  diet  derived  fatty  acids  gamma  linolenic  acid  (GLA)  and eicosapentanoic  acid  (EPA) and  inhibitory
compounds  as  useful  approaches  to  target  tissue  invasion  and  metastasis  as  well  as  other  hallmark  areas
of  cancer.  Together,  these  strategies  could  represent  new,  inexpensive,  low  toxicity  strategies  to  aid  in
the  management  of  cancer  metastasis  as  well  as  having  holistic  effects  against  other  cancer  hallmarks.
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. Introduction
The chain of events leading to the malignant transformation of
ells, whether through genetic or epigenetic alterations, is com-
lex. Malignant cells possess key hallmarks, namely, uncontrolled
rowth potentials and the ability to invade surrounding tissues and
etastasize [1]. Cancer cells likely possess these innate abilities to
ome extent, though the degree and timing of invasion and metas-
asis may  vary due to the genetic and epigenetic heterogeneity
ithin the tumor and further signals from extrinsic factors, such
s those within that particular microenvironment [2].
Despite substantial effort dedicated to the early detection and
revention of cancer, most patients are likely to have micro- (not
isible using conventional methods) or macro- metastases by the
ime they come to medical attention [3,4]. Cancer patients, both
arly and late stage, dependent on life span, are likely to develop
etastasis. This metastatic spread of the primary tumor accounts
or over 90% of patient mortality associated with solid cancers
1,4,5]. Despite this, research into the ﬁeld of metastasis, in compar-
son to other key events such as proliferation, etc., is lagging. This is
artly due to the complexity of the metastatic process but also due
o a lack of sufﬁcient funding and efforts into this area of research.
owever, signiﬁcant progress in this vital area of cancer research
as been witnessed over the past decade, though much remains to
e elucidated before we fully understand this pernicious condition
nd a number of signiﬁcant gaps remain to be ﬁlled before we  can
ruly understand this complex process.
Diagnosis and treatment of metastatic disease are vital areas in
he constant battle many patients face against cancer, yet effective
reatments are limited and substantial morbidity and mortality are
till associated with metastatic disease [5,6]. This, together with
he complexities surrounding the metastatic process (summarized
n Fig. 1) and the complex nature and heterogeneity of metastatic
umors, fully supports and justiﬁes further research dedicated to
he discovery of a less toxic means to treat this condition. This is the
ajor mission of getting to know cancer (GTKC). This review aims
o discuss key knowledge gaps, explore potential targets in tackling
etastasis and also potential methods, including phytochemicals,
mall molecule inhibitors and natural compounds in devising new
trategies for treating metastasis.
. Cellular properties and metastasis
.1. Cell–cell adhesion
In cancers derived from the epithelium, inter-cellular structures
nd cell–cell adhesion are key factors in maintaining a coher-
nt primary tumor mass [7,8]. Abnormalities in these structures,
hrough mutation or dysregulation, can lead to the dissociation
f the primary tumor and an enhanced potential for dissemina-
ion and metastatic spread of cancer cells to secondary locations
7–9]. Key structures involved in maintaining this adhesiveness
etween cells include adherens junctions (including desmosomes),
ight junctions (TJ) and gap junctions. While gap junctions con-
er a weak adhesion structure and TJs, a modest one, the adherens
unctions provide the most powerful source of adhesion in epithe-
ial cells. Perhaps one of the strongest and most studied regulators
f adhesion is E-cadherin (cadherin-1 or CDH1), a member of the Ltd. This  is  an  open  access  article  under  the CC  BY-NC-ND  license  (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
cadherin family of proteins. E-cadherin, together with associated
catenins, plays a key role in maintaining cell–cell adhesion and is
also involved in the regulation of the cell cycle regulators p27kip1
and p57kip2, which are involved in cell–cell contact inhibition in
normal epithelium, but which are lost or disturbed in cancer cells,
mainly due to the loss of E-cadherin in cancer cells [8,10,11].
Hence, reduced cell–cell adhesion not only enhances the poten-
tial for metastatic dissemination of cancer cells but also, through
loss of contact inhibition, promotes uncontrolled cell growth [7].
E-cadherin has also been established as a key mediator of the
epithelial – mesenchymal transition (EMT) process (discussed in
Section 2.4). Thus, enhanced expression of key cadherin molecules
could offer potential as a strategy to control metastatic dissemina-
tion, though realizing this potential has proved difﬁcult; thus far
there have been few reports identifying viable treatment options
in this regard. However, there are a number of noteworthy options,
namely the polyunsaturated fatty acids gamma linolenic acid (GLA)
and dihomo--linolenic acid (DGLA), both obtainable through the
diet. These have been reported to be key regulators of E-cadherin
and desmosomal cadherins in cancer cells and have also been
reported to have beneﬁcial effects for patients with several cancer
types including pancreatic cancer and breast cancer [12–15]. The
desirable effects of these essential fatty acids (EFAs) were blocked
by non-EFA, as long chained oleic derivatives on human cell lines
[16].
2.1.1. Claudins in cancer
The TJ complex is the apical most junctional complex in most
types of epithelial and endothelial cells. TJs are the gasket-like seals
that encircle each columnar epithelial cell around its apical pole.
They serve two  roles: (1) they help to maintain cell polarity by phys-
ically separating the apical and the basolateral membrane domains
and (2) they prevent free interchange of substances by diffusion
along the paracellular pathway between the luminal and antilu-
minal tissue ﬂuid compartments. TJs and their permeability are
important in the formation of the blood brain barrier, blood retinal
barrier and blood testis barrier. The TJ proteins can be sub-divided
into the integral membrane proteins such as occludin, tricellulin,
marvelD3, junctional adhesion molecules (JAMs) and the claudin
family (currently 27 members [17]) and the cytoplasmic proteins.
The cytoplasmic adaptor proteins are the zonula occludens or ZO
proteins, and are designated ZO-1, -2, and -3. These proteins link
the membrane proteins to the actin cytoskeleton. Traditionally,
research efforts focused on barrier and fence functions, however,
there is a new movement in the ﬁeld, which is to understand how
TJ proteins participate in cell proliferation, transformation, and
metastasis suppression. Recent studies have demonstrated the role
of TJs during epithelial tissue remodeling, wound repair, inﬂamma-
tion, and transformation into tumors. Epithelial multilayering was
associated with increased TJ permeability [18], activation of protein
kinase C (PKC)- [19] and phosphorylation of TJ proteins [20].
Studies focusing on the molecular architecture of the TJ have
now conﬁrmed that the claudin family of proteins is the inte-
gral component of the TJ. Loss of cell–cell adhesion is central to
the cellular transformation and acquisition of metastatic poten-
tial, however, the role the claudin family of proteins may  play in
a series of pathophysiological events, including human carcinoma
development, is only now beginning to be understood. Several
S246 W.G. Jiang et al. / Seminars in Cancer Biology 35 (2015) S244–S275
Fig. 1. The metastatic cascade and potential for therapeutic interruption. Changes in cellular properties are necessary to allow the development of an invasive phenotype
and  progression through the metastatic cascade. Key events of the cascade are outlined. Targeting such properties/events or the underlying signaling pathways using low
toxicity  drugs holds great potential to disrupt cancer cell progression through this cascade.
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laudin mouse knockout models have demonstrated their impor-
ant role in the maintenance of tissue integrity in various organs.
he mechanisms of claudin regulation and their exact roles in nor-
al  physiology and disease are being elucidated, but much work
emains to be done.
There are 27 types of claudins in mammals [17,21] and they are
ivided in classic and non-classic claudins based on their sequence
imilarity [21]. Classic claudins include claudins 1–10, 14, 15, 17
nd 19 and non classic claudins 11–13, 16, 18 and 20–24 [21].
laudins are found in epithelial, mesothelial, glial and endothe-
ial cells [22–24] with a molecular weight of around 20 kDa and
n cell membranes they are composed of two extracellular loops,
L1 and EL2, four transmembrane domains, one small 20 amino
cid long intracellular part between the two extracellular loops and
he intracellular aminoterminal and carboxyterminal ends [21,25].
he carboxyterminal end has regions which recognize the PDZ
post synaptic density protein, Drosophila disk large tumor sup-
ressor, and zonula occludens-1 protein) domains of ZO-1, ZO-2
nd ZO-3 [25]. The larger EL1 loop inﬂuences paracellular charge
electivity whereas the smaller EL2 loop binds to the correspond-
ng claudin of the neighboring cell [25]. Claudin expression and
unctions are regulated at multiple levels and by diverse mech-
nisms [26,27]. An important question related to regulation of
laudin expression and cancer is the role that claudins may  play
n the EMT process [28,29]. The paracellular barrier modulated by
laudin members can be affected by a wide range of physiologi-
al factors including cell signaling pathways, hormones, cytokines,
nd disruption of the cell–cell contacts. Post-translational modiﬁ-
ations, including phosphorylation, lipid modiﬁcation and removal
f claudins by endocytosis, appear to be potential mechanisms for
he regulation of claudins. Phosphorylation has been linked to both
ncreases and decreases in TJ assembly and function. Most claudin
roteins have putative serine and/or threonine phosphorylation
ites in their cytoplasmic carboxyterminal domains. For instance,
rotein kinase A (PKA) – mediated phosphorylation has been shown
o decrease assembly of claudin-3 into TJs [30], yet is necessary
or claudin-16 assembly and function [31]. Claudin-3 and -4 can
e phosphorylated in ovarian cancer cells by PKA, a kinase fre-
uently activated in ovarian cancer [30]. Claudin phosphorylation
ssociated with TJ disassembly is also enhanced by EPH receptor
1 (EphA1), which is recruited to bind to claudin-4 by forming a
omplex with ephrin-B1 [32]. Studies have implicated PKC in the
egulation of TJs through phorbol ester stimulation [30,33]. Fur-
hermore, modulation of mitogen-activated protein kinase (MAPK)
ignaling, speciﬁcally extra cellular signal-regulated kinase (ERK)
/2 and p38, as well as phosphatidylinositol 3-kinase (PI3K) have
 profound effect on TJ sealing and claudin expression [30]. TJs
re also remodeled at a more macroscopic level through strand
reaks and reformation [34]. Clathrin-mediated endocytosis plays
n important role in this process [35,36]. Claudins are internalized
y a unique mechanism, where the tightly opposed membranes
f the TJ are endocytosed together into one of the adjoining cells
24]. Host factors and cytokines can also inﬂuence TJ turnover and
laudin expression [37], for instance, interferon (IFN)-  increases
laudin endocytosis and TJ permeability [38]. Other inﬂammatory
ytokines, such as tumor-necrosis factor (TNF)- and interleukin
IL)-13, down regulate claudins and induce a marked increase in
aracellular permeability by epithelial cells in culture [39,40].
Growth factor receptors that are important in the regula-
ion of cell proliferation and survival including epidermal growth
actor (EGF), hepatocyte growth factor (HGF) and insulin like
rowth factor (IGF) receptors regulate claudin expression and cel-
ular distribution though once again in cell/tissue speciﬁc manner
28,29,41]. Claudin transcription can be regulated by the Snail/Slug
amily [42]. It is well established that overexpression of Snail in
pithelial cells induces EMT  and the acquisition of migratory and Biology 35 (2015) S244–S275 S247
in vitro invasive behavior. Snail and Slug bind to the E-box motifs
present in the human claudin-1 promoter which play a critical neg-
ative regulatory role in breast cancer cell lines that expressed low
levels of claudin-1 [42]. Caudal type homeobox 2 (Cdx-2), hepa-
tocyte Nuclear Factor 1-alpha (HNF-),  and GATA binding protein
4 (GATA-4) [43,44] can bind to the promoter regions of various
claudin genes and affect their expression. Furthermore, it has been
shown that colonic claudin-1 transcripts are regulated by Smad-4,
a known tumor suppressor as well as histone deacetylase (HDAC)
inhibitors and thus support a complex regulation at multiple lev-
els [45,46]. Collectively, the data provides an emerging picture of
the importance of claudin homeostasis in normal and pathological
tissue function, but there remains much to be learned, especially
regarding whether it may  be possible to identify a distinct claudin
signature in the initiation and progression of various tumor types.
Alterations in claudin expression proﬁles during tumorigene-
sis begs the question of how claudins are regulated in different
tissues in both normal and pathological situations. Tan et al. [47]
have shown that the expression and distribution of claudin-1 is
associated with cell dissociation status in pancreatic cancer cells
through MAPK 2 activation. By contrast, claudin-7 has been found
to be decreased in invasive ductal carcinomas [48], head and neck
cancer [49] and metastatic breast cancer [37]. On  the other hand,
claudin-3 and -4 are frequently elevated in various cancers includ-
ing pancreatic ductal adenocarcinoma, prostate, uterine, ovarian
cancer [38] and breast cancer [50] while hepatocellular and renal
carcinomas expressed lower levels of claudins-4 and -5 [22]. While
lower expression of claudin-2 was also seen in breast and pros-
tatic carcinomas, expressions of claudin-1 and claudin-7 that were
undetectable in normal cervical squamous epithelium increased
in the cervical neoplasia [22,51]. Intriguingly, recent studies have
shown that expression of certain claudins, especially claudin-1 and
claudin-4, increases during metastasis and genetic inhibition of
their expression has a profound effect on the metastatic abilities
of cancer cells though in a tissue speciﬁc fashion [52–54]. There is
the possibility that mutations in claudins may be causal to tumor
formation. However, to date there is no systematic sequence data
on claudins in any tumor type. On the other hand, gene silenc-
ing due to promoter hypermethylation is a common feature of
human cancers [55] and it has been suggested to underlie the down-
regulation of claudins in certain tumors. For example, a CpG island
was identiﬁed within the coding sequence of the claudin-4 gene,
and treatment with a methyl-transferase inhibitor restored expres-
sion of the protein in primary cultures prepared from high-grade
human bladder tumors [56]. Furthermore, claudin-4 expression
also correlated with its gene methylation proﬁle in healthy and
tumoral bladders from 20 patients and claudin-6 expression is par-
tially silenced by promoter CpG island hypermethylation in MCF-7
breast carcinoma cells, while a synergistic effect of a demethylator
and histone deacetylase inhibitors upregulates the expression of
endogenous claudin-6, and sensitizes the cells for apoptosis [57].
Intuitively, the mechanism by which decreased claudin expression
might lead to the compromised TJ function and thus, neopla-
sia is easy to comprehend, but how increased claudin expression
contributes to neoplastic progression is less clear. One plausible
mechanism is that upregulation or aberrant tissue expression of
certain claudins may  contribute to neoplasia by directly altering TJ
structure and function. Furthermore, it is postulated that claudins
may  also affect cell signaling pathways. Claudin proteins are likely
involved in signaling pathways via binding domains to ZO-1 at their
carboxyl terminus [58].
Cell–cell adhesion proteins are known to play an important role
in cellular transformation when displaced from their normal mem-
brane localization and could serve as oncogenic molecules, the
best studied molecule being -catenin [59]. A similar functional
heterogeneity could be postulated for claudins, however, further
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tudies are needed to support such a notion. An increase in claudin-
 expression has been reported in human primary colon carcinoma,
n metastasis samples and in the cell lines derived from primary
nd metastatic tumors compared to their normal counterparts [54].
rucially, there was nuclear localization of claudin-1 in a signiﬁ-
ant subset of colon cancer samples, particularly among the subset
f liver metastatic lesions. Nuclear localization of several cell junc-
ion proteins (-catenin, ZO-1, ZO-2) is known to be correlated with
ncogenic transformation and cell proliferation [60]. Mutants of the
J protein ZO-1 that no longer localize at the plasma membrane
nduce dramatic EMT in Madin-Darby canine kidney I cells [61].
imilarly, genetic manipulations of claudin-1 expression in colon
ancer cell lines induced changes in cellular phenotype, with struc-
ural and functional changes in markers of EMT, and had signiﬁcant
ffects upon the growth of xenografted tumors and metastasis in
thymic mice. Notably, regulation of E-cadherin expression and -
atenin/Tcf signaling emerged as one of the potential mechanism
nderlying claudin-1 dependent changes and thereby suggested
omplex interplay between different cell–cell adhesion molecules
54]. Expression of speciﬁc claudin family members can be reg-
lated by the wingless-type MMTV  integration site family (Wnt)
ignaling pathway. Claudin-1 and claudin-2 are shown to be target
enes regulated by -catenin signaling [62,63].
Metastasis is a complex phenomenon that requires a number
f speciﬁc steps such as decreased adhesion, increased motil-
ty and invasion, proteolysis, and resistance to apoptosis [64].
laudin-5 promotes processing of pro-matrix metalloproteinase-2
pro-MMP-2) by membrane type 1-MMP  (MT1-MMP). Expression
f claudin-5 not only replaced tissue inhibitors of metallopro-
einases (TIMP)-2 in pro-MMP-2 activation by MT1-MMP  but
lso promoted activation of pro-MMP-2 mediated by all MT-
MPs  and MT1-MMP  mutants lacking the transmembrane domain
DeltaMT1-MMP) [65]. It appears that interaction of MMP  with
laudins might play an important role in tumorigenesis, inva-
ion and metastasis mediated by claudin expression. It has been
bserved that overexpression of claudin-1 in colon cancer cells
ncreased activity of both MMP-2 and MMP-9 while inhibition of
laudin-1 resulted in a signiﬁcant decrease in MMP-9 activity [54].
imilarly, overexpression of claudin-3 or 4 in ovarian epithelial cells
ncreased MMP-2 activity [52]. An increase in mRNA transcription
nd protein expression of MT1-MMP  was also observed in claudin-
0 overexpressing cells, in which claudin-1, -2, and -4 were also
pregulated, suggesting that the expression of claudin-10 in can-
er cells may  dysregulate the expression of other claudin family
embers [66].
Most malignant tumors are derived from, and most pathogens
nvade the body via the epithelium. The epithelium is therefore a
otent target for improving drug absorption, treating cancer, and
uring infectious diseases. Modulation of TJ seals is a popular strat-
gy for improving drug absorption. TJs compartmentalize the apical
nd basal membrane domains of epithelial cells, leading to the for-
ation of cellular polarity. Loss of cell–cell interaction and cellular
olarity, which often occurs in cancer cells during carcinogene-
is, leads to exposure of TJ components on the cellular surface.
he claudin family of proteins is an attractive target for antitu-
or  therapy considering the epithelium-speciﬁc expression and
he high speciﬁcity of claudin expression patterns in cancer. It is
orth mentioning that claudin family members are expressed in
 precise tissue-speciﬁc manner and thus could serve as tumor
peciﬁc biomarkers. In this regard, a set of four markers, includ-
ng claudin-3, was found to be sufﬁcient to accurately identify
ll 158 ovarian cancers tested, including eight early-stage serous
ancers [67]. Furthermore, claudin expression may  be used as a
rognostic indicator because high claudin-1 expression has been
hown to be associated with tumor progression and metastasis in
olon cancer [68]. At the same time, in breast cancer, claudin-1 Biology 35 (2015) S244–S275
expression is differential between the subtypes and low versus high
claudin-1 expression helps identify highly aggressive triple nega-
tive breast cancer [69]. Similarly, claudin-10 expression has been
shown to be an independent prognostic factor for hepatocellular
carcinoma recurrence after curative hepatectomy [70]. Regarding
the identiﬁcation of the claudin family of proteins as tools to iden-
tify and/or classify tumor types, serial analysis of gene expression
(SAGE) studies of the breast [71] and ovarian [72] cancers have
allowed for the ﬁrst time the identiﬁcation of speciﬁc claudin fam-
ily members as potential biomarkers for these cancers. Although
large scale analysis in a clinical setting will be required to estab-
lish such potential of claudins, basic research on claudins is likely
to remain valuable for providing important insights into normal
and neoplastic cellular physiology. Preclinical studies have shown
that tumor cells overexpressing claudins can be successfully tar-
geted via several approaches, including the use of anti-claudin
antibodies as well as the cytolytic enterotoxin from Clostridium
perfringens.  However, most of the studies have concentrated pri-
marily upon claudin-3 and claudin-4 [73]. Both of these proteins
have been identiﬁed as targets of C. perfringens enterotoxin (CPE)
and have been reported to be overexpressed in multiple tumor
types including ovarian and prostate cancer. Yet another poten-
tial approach that has been suggested is the use of claudins as drug
delivery system using Pseudomonas aeruginosa exotoxin A (PE). PE
is widely used in cancer-targeting studies as it binds to the cell
surface and is internalized via endocytosis. Following this, a PE frag-
ment, protein synthesis inhibitory factor (PSIF), escapes from the
endosome to the cytosol [74], where it inhibits protein synthesis
by inhibiting elongation factor 2. PSIF lacks the receptor-binding
domain of PE, and fusion of a tumor antigen such as claudins with
PSIF is a promising strategy for cancer-targeting therapy. Therapies
speciﬁc to certain claudin family members could also serve as adju-
vant therapies. Highly increased and cytosolic/nuclear claudin-1
expression in colon cancer has been reported [54,75] and claudin-1
dysregulation modulates the balance between the Notch- and Wnt-
signaling to dysregulate colonocyte differentiation and promotes
tumor growth and progression. Since Notch and or Wnt-signaling
inhibition carries inherent high toxicity, the use of claudin-1 based
therapy may  provide an alternative.
2.2. Cell–matrix adhesion
Interaction and adhesion between cells and the surrounding
extracellular matrix (ECM) classically involves cell surface integrins
which interact and bind ECM protein components [76]. Functional
integrins consist of a heterodimer structure made up of different
- and - subunits and different integrin structures possess dif-
fering afﬁnities for different matrix proteins [76]. The interaction
between integrins and the ECM triggers a series of intercellular
events that not only results in the adhesion of the cell to the ECM
but also forms a mechanism for communication between intracel-
lular events and the surrounding ECM. This process of cell–matrix
adhesion is essential for the attachment of cancer cells to the sur-
rounding matrix and subsequently the degradation of the matrix
barrier [9]. A number of integrins have been linked to metastatic
likelihood and cancer and/or stromal cells may  deposit ECM pro-
teins that again can enhance metastatic progression. Blocking the
extracellular part of the cell–matrix adhesion by means of antibod-
ies, small peptides, and other natural- and phytochemicals has been
demonstrated and has been covered by another article in this issue.
However, blocking the intracellular signaling event has also proved
to be a useful approach in inhibiting this important event during
cancer metastasis. Key events following the matrix–integrin inter-
action include activation of the focal adhesion kinase (FAK), paxillin
and downstream chain signaling events [77]. Thus, inhibiting FAK
and paxillin has become a hotly pursued approach in recent years.
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D44 represents another key cell adhesion molecule that holds
otential as an antimetastatic target both through its role in inter-
cting with other cell types and the ECM. The CD44 gene, located
t human chromosome 11p13, encodes the CD44s and CD44v iso-
orms, which arise through alternative splicing. CD44s and CD44v
soforms share the extracellular globular region that includes
inding sites for hyaluronan, collagen, laminin and ﬁbronectin
s well as the cytoplasmic tail region that includes binding sites
or ERM domain proteins (Ezrin, Radixin and Moesin), Ankyrin
nd S6 kinase related kinase (SRK). CD44 functions as a hyaluro-
an receptor, co-receptor for growth factors and as an adhesion
olecule [78–82]. CD44 is involved in the malignant phenotypes
f cancer stem cells, including EMT, invasion, metastasis, recur-
ence, resistance to chemotherapy and resistance to radiation
herapy [82–85], which clearly indicates that CD44 is a potential
arget of cancer therapy. Humanized anti-CD44v6 monoclonal anti-
ody BIWA-4 (bivatuzumab), paclitaxel-conjugated hyaluronan
rodrug HYTAD1-p20 (ONCOFID-P), SN-38-conjugated hyaluronan
rodrug ONCOFID-S, hyaluronan–irinotecan complex and other
yaluronan-conjugated drugs or siRNAs have been developed as
ancer therapeutics [86]. Therapeutics targeted to cell–matrix
dhesion may  represent a useful strategy to block cancer cells from
ettling on and subsequently penetrating vascular or cavity lining
nd hence negatively impacting their ability to establish secondary
umors in the new site.
.3. Cellular migration
While essential to normal development and homeostasis, the
rocess of cellular migration is also a trait essential for metasta-
is. Enhanced migration is key across the metastatic cascade and
s involved in the initial scattering of cells and migration from the
rimary tumor, the penetration of the basement membrane and
CM and intravasation and extravasation of vessels. The migration
f cells requires a number of intra- and extra-cellular events such
s the detection of extracellular signals by the cells, synthesis of cell
urface proteins and the coordination of intracellular signaling and
ytoskeleton proteins. Throughout the literature, cell migration has
een tightly linked to cancer progression and metastasis. Numer-
us proteins and pathways have been implicated in altering the
igratory potentials of cancer cells and therefore their aggressive
ature [87,88]. Hence, given its essential role in cancer progression,
reatments that inhibit cell migration or such proteins/pathways
nvolved in enhancing cellular motility represent an attractive
trategy for controlling metastatic dissemination. While in nor-
al  physiology cellular migration is less active, there are processes
here it is essential, such as wound healing, and hence must be
aken into consideration. Currently there are many compounds that
nhibit cellular migration, although very few have been tested in a
linical setting.
.4. EMT
The process through which epithelial cells undergo a series
f morphological and biochemical changes to take on a more
esenchymal phenotype is known as epithelial–mesenchymal
ransition. EMT  is widespread throughout normal development
ut has also been linked to the establishment of a more invasive,
otile cancer cell phenotype facilitating detachment and dissem-
nation away from the primary tumor [89–92]. EMT  involves the
oss of cell–cell adhesion and the polarized epithelial morphology
hrough the characteristic loss of epithelial cell junctional pro-
eins such as E-cadherin, claudins and ZO-1, and a subsequent
ncrease in mesenchymal markers such as N-cadherin, vimentin
nd ﬁbronectin and cytoskeletal reorganization [91,93]. Indeed, the
oss of E-cadherin and subsequent replacement with N-cadherin Biology 35 (2015) S244–S275 S249
(‘cadherin switching’) is a characteristic of EMT, seen in many can-
cer types and is thought to account somewhat for the enhanced
invasive and motile properties of cancer cells [8]. Unsurprisingly,
alterations in cell adhesion molecules (CAM) such as E-cadherin,
impact the processes of cell–cell adhesion and cell–matrix adhe-
sion and subsequently their metastatic potential. E-cadherin plays
an essential role in the adhesion of cells and tissues and together
with other members of the adhesive complex, such as -catenin,
regulates cell adhesion, signaling and transcription in cancers and
control metastatic progression [94]. Indeed, studies have demon-
strated an association between loss of E-cadherin and -catenin
expression with enhanced tumor cell invasiveness [95]. Other
work has demonstrated an inverse correlation between E-cadherin
expression and tumor cell invasion and motility and similarly with
metastatic disease in cancer patients [96]. The translocation of -
catenin from the adhesive structure to the nucleus, an event leading
to transcriptional activation of a number of target genes has also
been demonstrated to correlate with development of a mesenchy-
mal  phenotype [97,98].
Initiation signals, such as HGF, EGF and transforming growth
factor  (TGF-) are believed to onset the EMT  process, result-
ing in upregulation of EMT-inducing transcriptional factors such
as Snail, Slug and Twist [99–102]. Slug, Snail and Twist have been
implicated in inﬂuencing the expression of EMT proteins and are
hence linked to metastasis [103–105]. For example Slug and Snail
are involved in the down-regulation of E-cadherin [99,106] and the
expression between Snail and E-cadherin is inversely correlated
in a number of cancers including breast cancer [107]. Similarly,
as discussed in Section 2.1.1, Snail exerts regulatory effects over
members of the TJ such as the claudins. These initiation factors also
act on other effector molecules to bring about EMT, such as the
MMP  family. Members of this family of proteinases play key roles
in matrix-degradation, invasion, motility and adhesion and are fre-
quently dysregulated in cancer progression. Slug and Snail have
both been implicated in the upregulation of MMP-2 and MMP-9
and subsequent EMT  initiation [108].
The process of EMT  and subsequent acquisition of an inva-
sive, motile phenotype with enhanced likelihood of invasion and
dissemination represents a key interest in cancer research. Thera-
peutic strategies that can speciﬁcally target this process in cancer
cells are likely to be effective in reducing the metastatic potential
of tumor cells.
2.5. Molecular networks in the tumor microenvironment
It is now well established that solid tumors are not sim-
ply aggregates of replicating neoplastic cells but are also living
entities, composed of numerous cell types, whose complexity
approaches, and may  even exceed, that of normal healthy tissues.
Many non-malignant cell types, referred to as the stroma, populate,
at majority, the solid tumors. These non-malignant cells include
ﬁbroblasts, resident epithelial cells, pericytes, myoﬁbroblasts, vas-
cular and lymphovascular endothelial cells and inﬁltrating cells of
the immune system. During malignant progression, neoplastic cells
acquire the ability to recruit, incorporate and reprogram the biol-
ogy and the function of these healthy host cells, thus providing
them with support, essential nutrients and weapons to hamper
antitumor immune activity. In turn, the recruited non-malignant
cells respond by enhancing the neoplastic phenotype of the nearby
cancer cells, which again feed signaling back to the stroma to con-
tinue its reprogramming. Thus, the previous idea that the malignant
phenotype of tumor cells was  exclusively determined by cell-
autonomous genetic and epigenetic alterations is now replaced by
the hypothesis that the malignant progression of cancer not only
depends on tumor cells’ genetic aberrations but also on the bidi-
rectional, dynamic and intricate network of interactions between
S250 W.G. Jiang et al. / Seminars in Cancer Biology 35 (2015) S244–S275
Fig. 2. Cellular interactions within the tumor microenvironment. Numerous interactions between cell types are involved throughout tumor progression and metastasis.
Communication between main components of the surrounding microenvironment play vital roles in enhancing metastatic potential, epithelial to mesenchymal transition
(EMT),  immune-evasion, mesenchymal to epithelial transition (MET) and angio- and lymphangio-genesis.
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he cells of the stroma and cancer cells within the tumor microen-
ironment [109,110] (Fig. 2).
Among the non-malignant cells that inhabit the tumor
icroenvironment, cancer-associated ﬁbroblasts (CAFs) and tumor
nﬁltrating-immune inﬂammatory cells are noteworthy because
f the roles they play in tumor development and malignant pro-
ression. CAFs secrete factors that act on tumor cells in both
aracrine and autocrine fashions, thus resulting in a more aggres-
ive cancer phenotype. Across most cancers, activated CAFs secrete
 wide variety of growth factors, chemokines, collagens, and
CM-modifying enzymes, which collectively supply a communica-
ion network and an altered three-dimensional ECM scaffold that
ogether govern proliferation of cancer cells and tumor invasion
nd metastasis across tissue types. They also contribute to tumor
rogression by recruiting tumor-promoting immune cells and sup-
orting angiogenesis. The tumor inﬁltrating-immune cells include
he tumor-associated macrophages (TAMs), myeloid-derived sup-
ressor cells (MDSCs), dendritic cells (DCs), tumor inﬁltrating T
ells, regulatory T cells (Tregs) and mast cells [109]. Tumor cells
ecrete chemokines and cytokines that are able to recruit mast cells,
Cs, TAMs and MDSCs. Tumor cells also activate mast cells, promote
he expansion of the MDSCs and the polarization of TAMs. Further-
ore tumors both inhibit DC maturation through IL-10 secretion,
hus leading to antigen-speciﬁc anergy, and reprogram the DCs,
nducing them to exert immunosuppressive or angiogenic func-
ions, thus resulting in an immunosuppressive and inﬂammatory
umor microenvironment. Once recruited to the tumor microen-
ironment, these immune cells can contribute to the malignant
rogression of the cancer-cell phenotype by supporting tumor
roliferation, survival, invasion, metastasis, angiogenesis and ECM
emodeling.
In cancer cells, the constitutive activation of various signaling
athways (including MAPK, signal transducer and activator of
ranscription 3 (STAT3) and -catenin pathways) results in the
ecretion of cytokines which modulate the recruitment and
unction of the stromal cells. In particular, the tumor-derived
egulated on activation, normal T cell expressed and secreted
RANTES)/Chemokine (C–C motif) ligand 5 (CCL5) cytokine stimu-
ates CAFs to externalize the S100A4 protein, which stimulates
umor-cell survival and migration, up-regulation of the MMPs,
own-regulation of TIMPs, activation of the nuclear factor of kappa
ight polypeptide gene enhancer in B cells (NF-B) and MAPK path-
ays, inﬁltration of T cells and ﬁnally, up-regulation of RANTES,
hus generating a signal ampliﬁcation loop. RANTES also induce
ngiogenesis and act as chemoattractants for additional effector
mmune cells. Tumor-derived stem cell factor (SCF) promotes the
ecruitment and activation of mast cells and the MDSC expan-
ion. Tumors also secrete the thymic stromal lymphopoietin (TSLP)
nd bone marrow stromal cell antigen 2 (BST2). TSLP induces
Cs to express OX40 ligand, which directs CD4+ T cells to gen-
rate TH2 cells secreting IL-4 and IL-13. These cytokines prevent
umor cell apoptosis and indirectly promote the proliferation of
umor cells by stimulating TAMs to secrete EGF. BST2 is a ligand
f immunoglobulin-like transcript 7 (ILT7), which is expressed on
Cs surface. The interaction of ILT7 on DCs with BST2 on tumor
ells results in inhibition of IFN- and pro-inﬂammatory cytokines
roduction by DCs with immunosuppressive effects.
Oncogene activation and subsequent signal activation in can-
er cells trigger multiple cascades thus resulting in the secretion
f several immunosuppressive molecules, including TGF-, IL-10,
L-6, vascular endothelial growth factor (VEGF), CCL2/monocyte
hemoattractant protein 1 (MCP1), cyclooxygenase-2 (COX2), that
nduce the immunosuppressive immune cells. Production and
ecretion of these factors by both cancer and surrounding cells
nhance tumor cell proliferation, migration and invasion. Further-
ore it enhances the production of immunosuppressive cytokines Biology 35 (2015) S244–S275 S251
and chemokines, including TGF- itself, IL-10 and CCL2/MCP1.
TGF- and the potential for targeting this signaling pathway in
cancer is discussed in Section 4.2. A plethora of recent reports
has painted a consistent picture of how stromal cells (CAFs and
inﬂammatory cells) can promote malignant progression. Indeed,
within the primary tumor microenvironment, the stromal cells
provide potent oncogenic signals, such as TGF-, HGF, EGF, Wnt,
and basic ﬁbroblast growth factor (bFGF), which stimulate cancer-
cell proliferation, survival and invasion, thus facilitating metastasis.
Moreover, these cells produce several angiogenesis-modulating
enzymes, such as VEGF, thymidine phosphorylase, MMP-2, MMP-
7, MMP-9, MMP-12, COX2, urokinase plasminogen activator (uPA)
and cathepsins B and D, which together degrade the ECM, again
promoting metastasis. TAMs promote carcinoma-cell motility and
invasion through a paracrine signaling loop between the tumor
cells and the TAMs. Within this loop the macrophages express
EGF, which promotes formation of elongated protrusions and cell
invasion by carcinoma cells. In addition, EGF promotes the expres-
sion of colony stimulating factor 1 (CSF-1) by the carcinoma cells,
which further promote the expression of EGF by macrophages
generating a positive-feedback loop. The secretion of stromal-
cell-derived factor 1 (SDF1), also known as chemokine (C–X–C
motif) ligand 12 (CXCL12), by TAMs and CAFs at a tumor site
can enhance the invasion, intravasation, metastasis formation and
recruitment of MDSCs, TAMs and endothelial cells to the primary
tumor. This enhancement of invasion and intravasation depends
upon chemokine (C–X–C motif) receptor 4 (CXCR4) signaling, and it
is most likely to occur through activation of CXCR4 on macrophages,
which results in increased paracrine interactions with tumor cells
in the tumor microenvironment. Increased CXCL12/SDF1 secretion
also gives rise to an increased microvessel density, which might
also be mediated by TAMs and might contribute to an altered tumor
architecture, thus resulting in increased intravasation through the
presence of a higher density of entrance sites into the blood, with
a corresponding increase in the formation of metastases. The sig-
niﬁcance of CXCL12/CXCR4 signaling in breast cancer invasion and
metastasis is widely appreciated. CXCR4 expression in breast can-
cer cells has been shown to increase metastasis through the homing
of tumor cells to sites of increased CXCL12 expression, such as the
lymph nodes. Similarly, the interaction of CXCL12/SDF1 and CXCR4
expressed on mammary adenocarcinoma MTLn3 cells increases the
chemotactic and invasive behavior of these cells to CXCL12/SDF1,
as well as their motile behavior within the primary tumor and their
ability to intravasate. TAM-derived CCL17 and CCL22 chemokines
preferentially attract T cell subsets that are devoid of cytotoxic
functions, such as Tregs and Th2 lymphocytes. TAM-derived CCL18
recruits naïve T cells, which induce T cell anergy. Within the tumor
microenvironment IL-10, secreted not only by immune cells, but
also by CAFs and tumor cells, is the main cytokine responsible
for the establishment of the immunosuppressive milieu. Further-
more, IL-10, together with IL-4, IL-6 and IL-13, induces monocyte
differentiation toward a mature M2-polarized phenotype that is
characteristic of TAMs. At the tumor site, the IL-1 and IL-6
cytokines, S100A8 and S100A9 pro-inﬂammatory proteins and the
chemoattractant molecules CCL2/MCP1, CXCL12/SDF1 and CXCL5
are the main factors that are responsible for the recruitment and
the induction of MDSCs. VEGF is one of the main factors responsi-
ble for the expansion of MDSCs, while IL-4, IL-13, IFN-, IL-1 and
TGF- turn on their suppressive functions. MDSCs produce high
levels of IL-17, which further exacerbates the inﬂammatory tumor
microenvironment.
The growing body of evidence regarding the roles played by
non-malignant cells of the tumor microenvironment in promot-
ing tumor progression indicate that it is conceivable that these
cells can serve as novel therapeutic targets in the cancer treatment.
For this purpose, several therapeutic approaches that use small
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Table 1
Effects of approved and experimental targeted agents on tumor cells and tumor microenvironment stromal cells.
Drug Drug class Target Effect on tumor Effect on the immune system References
STI571 (Gleevec or
imatinib mesylate)
Small molecule
inhibitor
PDGFR and
c-Kit
Reduces microvessel density Prevents mast cell proliferation
and survival
[283,284]
Bevacizumab Monoclonal
antibody
VEGF Blocks angiogenesis Increases DC maturation, shifts DC
differentiation toward mature DCs
instead of MDSCs and increases DC
priming of T cells
[285,286]
IM-2C6 Antibody VEGFR Blocks angiogenesis NA [287]
SU5416 Small molecule
inhibitor
VEGFR Reduces vascular density NA [288]
MMI-166 Small molecule
inhibitor
MMP-2 and
MMP-9
Suppresses MMP-2 and MMP-9
activities; inhibits angiogenesis
and tumor growth
NA [289]
S-3304 Small molecule
inhibitor
MMP-2 and
MMP-9
Inhibits MMP-2 and MMP-9 NA [290]
Dasatinib Small molecule
inhibitor
c-Kit, ABL, SRC,
PDGFR
Induces apoptosis in leukemic cell Induces apoptosis in mast cell [117]
Dipyridamole Small molecule Wnt, MAPK
and NF-B
pathways
Decreases tumor growth and
metastasis
Decreases TAM and MDSC
inﬁltration
[118]
Bindarit Small molecule CCL2/MCP1 Decreases tumor growth and
metastasis
Decreases TAM and MDSC
inﬁltration
[119]
Upanap-126 RNA aptamer uPA Delays the proteolitic conversion
of  pro-uPA to active uPA; inhibits
tumor cell invasion; reduces the
tumor cell intravasation and
dissemination
NA [111]
ATN-658 Monoclonal
antibody
uPA receptor
(uPAR)
Decreases tumor cell invasion and
migration and tumor volume
NA [112]
L2G7/Rilotumumab Monoclonal
antibody
HGF Inhibits the tumor growth NA [113,291,292]
Trastuzumab Monoclonal
antibody
HER2 Blocks growth signals Primes antitumor CTLs, boosts NK
secretion of IFN- and mediates
potent antibody-dependent
cellular cytotoxicity
[293]
Cetuximab Monoclonal
antibody
EGF receptor
(EGFR)
Blocks growth signals Immune activating: increases MHC
class I and MHC  class II expression;
augments DC priming of
tumor-speciﬁc CTLs.
[294]
MGA271 Monoclonal
antibody
B7-H3 NA Mediates potent
antibody-dependent cellular
cytotoxicity
[295]
AMD3100 Small molecule CXCR4/CXCL12
(SDF1)
signaling
Sensitizes cancer cells to
chemotherapy: inhibits tumor
growth
Reduces the recruitment of
bone-marrow derived cells
[114–116]
Celecoxib Small molecule
inhibitor
COX2 NA Decreases both MDSC numbers
and function
[296]
5-Fluorouracil Small molecule Thymidylate
synthase
Promotes the cytotoxicity of tumor
cells
Induces MDSC apoptotic cell death [297]
All-trans-retinoic acid
(ATRA)
Vitamin A
derivative
NA NA Reduces MDSCs [298]
Sclareol Phytochemical NA Decreases the tumor size Decreases the number of Tregs [120]
Temozolomide Small molecule DNA Promotes the cytotoxicity of tumor Reduces the number of Tregs [121]
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olecule inhibitors, antibodies or phytochemicals that speciﬁcally
arget molecules and signaling pathways involved in the recruit-
ent, activation and function of tumor inﬁltrating non-malignant
ells have been tested in both animal models and human. Table 1
ummarizes the most up-to-date drugs available with potential
se in cancer therapy, known effects on tumor cells and activity
gainst tumor-stromal microenvironment communications. Sev-
ral strategies to inhibit either CAF activation or CAF-derived
actors (e.g. HGF, uPA, CXCL12/SDF1) have been applied in pre-
linical studies of cancer therapies and the results have shown
fﬁcacy in the inhibition of tumor growth and invasion [111–116].
imilarly, several immunotherapeutic approaches have been devel-
ped to target immune cells that inﬁltrate the tumor. Some
nti-angiogenic agents impair proliferation and survival of mast
ells and induce DC maturation and their antitumor activity (e.g.
TI571 and bevacizumab). The impairment of the stem cell factor(SCF)/c-Kit signaling pathway by dasatinib induces apoptosis of
both tumor cells and mast cells [117]. Several immuno-therapeutic
strategies that target MDSCs and that can neutralize their immuno-
suppressive effects have been reported in both animal models and
human. These strategies include approaches that are aimed at the
induction of differentiation of these immature cells [e.g. all-trans-
retinoic acid (ATRA)], or of a decrease in their number and tumor
inﬁltration (e.g. dipyridamole and bindarit), or at interfering with
their immunosuppressive functions (celocoxib), or killing MDSCs (5
ﬂuorouracil- or 5FU). Interestingly, dipyridamole [118] and bindarit
[119] decrease the inﬁltration not only of MDSCs but also of TAMs in
breast and prostate cancer proof of concept animal model studies.
Finally sclareol and temozolomide reduce tumor growth and the
number of tumor inﬁltrating Tregs [120,121]. Therefore, although
further studies will be needed to determine which cell(s) is/are the
best therapeutic target(s) and which drugs are the most efﬁcient
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nd selective, there is no doubt that the therapeutic targeting of
umor microenvironment cells represents a valuable strategy to
omplement conventional anticancer strategies.
.6. Cancer stem cells (CSC)
Cancer stem cells (CSC) present an exciting yet somewhat con-
roversial ﬁeld in cancer research. In the cancer stem cell model of
arcinogenesis there is a hierarchical organization of cancer cells.
he CSC represent a highly tumorigenic sub-population of cancer
ells that can be isolated from other cancer cells in the same tumor.
hese highly tumorigenic cells have been proposed as crucial to
he growth and development of primary tumors and are believed
o be resistant to conventional therapy and therefore likely to be
esponsible for disease recurrence and treatment failures. CSC were
rst isolated in acute myelogenous leukemia (AML) and subsequent
nvestigations of solid tumors have revealed the presence of highly
umorigenic cancer cells (CSC) in essentially every solid cancer type
ncluding breast, lung, colon, pancreas, head and neck [122–127].
The critical characteristics of a CSC require these cancer cells
o be: tumorigenic, able to reproduce the original tumor het-
rogeneity including both the tumorigenic and non-tumorigenic
ubpopulations of cancer cells, self-renewing, and separable from
he other cancer cells. CSC typically represent only a small sub-
opulation (<10%) of the entire cancer cell population. A variety
f cells surface markers and biological markers have been used to
solate the CSC population from other cancer cells, including CD24,
D44, CD26, CD133, epithelial speciﬁc antigen (ESA), and aldehyde
ehydrogenase activity (ALDH) [128]. So far, no single marker or
ombination of markers has proven useful for isolating CSC from
very tumor site. The expression of CSC markers in primary tumors
as been found in some studies to be associated with tumor stage,
rognosis and response to therapy. It is a logical extension of the
SC theory to hypothesize that, as CSC are the only cancer cells
hat can produce a primary tumor, CSC must also be essential for
he development of metastatic disease.
In breast cancer, cells characterized by high CD44 expression
nd low levels of CD24 expression (CD44+CD24−/low) have been
hown to encompass the CSC subpopulation of cancer cells [125].
nother marker for the identiﬁcation of CSC in breast cancer is high
evels ALDH expression, also a marker for many normal stem cell
opulations [123]. By comparing gene expression proﬁles between
LDH+ and ALDH− breast cancer cells, a 413-gene breast CSC sig-
ature was determined. Among the differentially expressed genes,
he gene encoding for the IL-8 receptor CXCR1/IL-8RA, previously
escribed to be involved in the regulation of cancer growth and
etastasis, was found. The ALDH + CSC derived from breast can-
er cell lines were shown to be signiﬁcantly more metastatic than
LDH− cells by intracardiac injection in Nonobese diabetic/severe
ombined immunodeﬁciency (NOD-SCID) mice indicating a pos-
ible role for CXCR1/IL8-RA in the metastatic potential of breast
SC. Additionally the same CSC-enriched populations gave rise to
xtra-pulmonary metastases in the pancreas, liver, spleen and kid-
ey [129]. Similar results have been shown in head and neck cancer
here the CSC collected based on CD44 expression were shown
o be essential for metastatic formation in a tail vein model and
n an orthotopic head and neck cancer model [130,131]. This data
upports the concept that CSC are critical to the development of
etastasis.
There is accumulating evidence of cellular heterogeneity
ithin the CSC compartment with some CSC exhibiting an
nhanced potential for the development of metastasis. Evidence
or metastatic and non-metastatic CSC was ﬁrst raised in cancer of
he pancreas. The pancreatic CSC population is deﬁned by CD133
xpression. In vivo studies of the CD133 + CSC revealed a subpopu-
ation of migrating CSC deﬁned by surface expression of CXCR4. Biology 35 (2015) S244–S275 S253
CXCR4 is a protein that has previously been implicated in can-
cer cell metastatic potential [132]. Using an orthotopic model of
pancreatic cancer only the migrating CSC population, expressing
CD133+CXCR4+, were able to establish liver metastasis. Inhibition
of CXCR4 signiﬁcantly reduced the CSC metastatic potential [133].
These results are signiﬁcant as the ﬁrst observation of the impor-
tance of the CSC phenotype to their metastatic potential as well as
the role of CXCR4 in regulating this behavior in CSC [134].
Additional evidence of the existence of different CSC subtypes
responsible for speciﬁc behaviors exists in colon cancer. It has
been reported that colon CSC have three distinct phenotypes; self-
renewing long-term (LT-TICs), tumor transient amplifying cells
(T-TAC), and delayed contributing (DC-TICs). Interestingly the self-
renewing LT-TICs were the only subpopulation of CSC able to
contribute to metastasis formation [135]. More recently, CD26 was
conﬁrmed as a marker for metastatic CSC in colon cancer [136].
None of the patients without CD26-expressing cancer cells in their
primary tumors developed metastases, while the majority of those
whose tumors contained CD26+ cells did. In animal models, both
CD26+ and CD26− cells were capable of giving rise to primary
tumors, however, only CD26+ cells had the capacity to produce
metastasis [137]. These reports conﬁrm the importance of CSC,
and more speciﬁcally the migratory subpopulations of CSC, to the
development of metastasis in colon cancer.
EMT  has been implicated as an important mechanism by which
cancer cells gain metastatic potential. Many cancer types have been
shown to exhibit EMT. EMT  is believed to represent a crucial step
toward cancer cells acquiring invasiveness and the potential to pro-
duce metastasis [138]. There is accumulating evidence that CSC
undergo EMT  and this ability has important regulatory functions
related to CSC behavior. Studies have revealed that EMT can induce
apparently differentiated cancer cells to gain a CSC-like phenotype
increasing their tumorgenicity and their ability to migrate to and
invade tissues distant from the primary tumor. Additionally, can-
cer cells undergoing EMT  have been shown to be enriched for CSC
[139]. CSC express many EMT  regulating factors including TWIST,
Snail and Slug suggesting these genes play an important regulatory
role in CSC behavior [140].
The preferential location of EMT  cells along the invasive front of
tumors and the association of EMT  with high Wnt  signaling levels
have been demonstrated. This includes the nuclear accumulation of
-catenin, evidence of Wnt  activation, observed in cells undergoing
EMT  at the invasive front [134]. Signals from the tumor microenvi-
ronment have been demonstrated to elicit Wnt  signaling in colon
cancer cells, inducing EMT  and allowing for their detachment and
spread from the primary tumor site. Observations regarding EMT
and Wnt  expression in locations within primary tumors where CSC
typically reside led to the concept of migrating CSC as proposed by
Brabletz et al. in 2005 [134].
EMT  has been shown to be a reversible process in that
mesenchymal-to-epithelial transition (MET) can transform mes-
enchymal cells back to their epithelial state. Similarly metastatic
CSC may respond to local cues to revert from their mesenchy-
mal  state back to their original epithelial state. Once the CSC have
returned to their original epithelial condition they can form grow-
ing metastatic deposits. It is highly likely that CSC lead to the
development of metastases by acquiring mesenchymal properties
that enhance their ability to migrate and invade and then transition
back to their epithelial phenotype to form a metastasis. The fac-
tors that regulate EMT  in cancer cells are being studied in multiple
cancer types but are not yet fully understood. The tumor microen-
vironment has been proposed as an important regulator of EMT  in
CSC including local factors such as hypoxia, cytokines including IL-6
and cancer associated cells including tumor associated ﬁbroblasts,
mesenchymal stem cells, and lymphocytes able to secrete diffusible
EMT-inducing signals [141,142].
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Although attractive and in agreement with many genetic anal-
ses and with the evaluation of CSC in primary tumors and animal
odels, to date the causative role of CSC in metastasis formation has
ot been formally proven. Metastases represent one of the key fac-
ors in treatment failures in patients with cancer. Recognition that
SC play a critical role in the development of metastasis is an impor-
ant step toward increasing our understanding of how metastasis
evelop. The factors that modulate the CSC metastatic phenotype
ave not yet been fully elucidated and require more intensive inves-
igation. This work will lead to more effective anticancer therapy
nd improved outcome for patients.
. Cancer cell dissemination and the metastatic cascade
.1. Organ speciﬁc metastasis
The predisposition of certain body sites or organs to house
etastatic cells and establish secondary tumors has been appar-
nt for centuries and has been famously explained in Paget’s ‘seed
nd soil’ theory of metastasis [143]. This theory dictates that a spe-
iﬁc tumor cell (the seed) will only establish in a particular suitable
rgan or location (the soil). Indeed, many cancers have an increased
ropensity to establish secondary metastasis at certain sites. For
xample, breast and prostate cancers appear to be predisposed to
etastasizing to the bone environment whereas gastrointestinal
ancers frequently metastasize to the lung and liver [2,144]. Indeed
 few organs represent the main secondary destination for most
ancers, namely, the liver, lung, bone and brain, while organs such
s the spleen and heart rarely host metastasis. The factors underly-
ng this organ speciﬁc predisposition for metastatic dissemination
y many cancer types are largely unknown and are widely being
tudied within the scientiﬁc community. Establishment of such fac-
ors may  again yield intuitive strategies to limit metastatic disease.
.1.1. Targeting bone metastasis
Bone metastases are a common complication of several types
f cancers, including breast, prostate and lung cancer. The occur-
ence of these bone metastases deeply impact the prognosis and
he quality of life of patients and are responsible for signiﬁcant
orbidity. Bone metastases are often osteolytic (due to signiﬁ-
ant bone destruction), sometimes sclerotic (due to an excess of
one formation) or mixed. Numerous mechanisms and factors are
nvolved in the invasion, colonization and establishment of tumor
ells in the bone microenvironment. The complex sequence of
vents that lead to the onset of bone metastases not only involves
rocesses common to any other metastasis but also processes that
re more speciﬁc to the bone tissue (tumor cell invasion in the
one environment, implantation of tumor cells in bone marrow,
steomimicry, deregulation of osteoblast\osteoclast activity) [145].
he current section illustrates progress made toward the under-
tanding, treatments and management of this particular form of
etastatic disease.
The spread of metastatic cells from the bloodstream to the bone
arrow involves factors that are produced by osteoblasts and
tromal cells in the bone marrow. Among these factors, a key role
s played by chemokines (CXCL12, CXCL13, chemokine (C-X3-C
otif) ligand 1 (CX3CL1), CCL22) that stimulate cancer cell migra-
ion to the bone marrow, since they express membrane receptors
orresponding to these chemokines [145]. For example, CXCL12
nd its receptor CXCR4 play an important role in bone tropism
f cancer cells and treatment with inhibitors of CXCR4 (AMD
100, T140) or CXCL12 (OTP-9908) has demonstrated efﬁcacy in
ecreasing the formation of bone metastases in experimental mod-
ls of breast cancer or prostate cancer [145,146]. In addition, some
roteins (bone sialoprotein, osteonectin, osteopontin, collagen) Biology 35 (2015) S244–S275
can stimulate bone matrix invasion by binding the surface of tumor
cells through speciﬁc membrane receptors such as integrins V3
and 21 [145] and it has been demonstrated that breast cancer
cells expressing V3 integrin and prostate cancer expressing
the V2, have higher incidence of bone metastases [147]. There
is preclinical evidence that V3 integrin inhibition is able to
prevent bone colonization by V3 expressing human breast
cancer cells [148]. Several ongoing clinical trials are evaluating the
anticancer effect of integrin antagonists in advanced refractory and
metastatic cancers, but only one phase I clinical trial is evaluating
integrin antagonists (GLPG0187) in cancer patients with bone
metastasis (NCT01313598) [149,150].
It has been demonstrated that the tyrosine kinase c-MET
promotes stemness phenotype, tumor growth, invasion, and
metastasis in several malignancies. In particular, c-MET is over-
expressed in prostate cancer cells and is associated with tumor
progression and metastatic invasion to bone [151]. Cabozan-
tinib (XL184) is an oral small molecule inhibitor of multiple
kinase signaling pathways including c-MET and vascular endothe-
lial growth factor receptor 2 (VEGFR2). A recent phase II
“randomized discontinuation” trial in patients with metastatic cas-
tration resistant prostate cancer (mCRPC) included 171 men  with
castration-resistant prostate cancer (CRPC from a larger phase II
randomized discontinuation trial that included multiple tumor
types treated with cabozantinib). The randomization was stopped
after 122 patients because of improvements in bone scans and a
decrease in pain. At the time the study was  halted, a group of 31
patients had been randomly assigned. In this group, there was a
marked improvement in the primary end point of progression-free
survival (PFS) in the patients receiving cabozantinib compared with
placebo (p < 0.001) [152]. Phase III trials are currently on ongoing.
Cathepsins are a class of globular lysosomal proteases that
belong to the papain-like cysteine protease family expressed in
a wide variety of tissues including the bone, where they appears
to be a key enzyme in bone matrix degradation [153]. Different
cancers express cathepsin K, including prostate and breast cancers
[154]. Until recently, a role for cathepsin K in bone metastasis had
been mainly attributed to its ability to degrade native collagen I, a
process necessary for the expansion of the tumor within the bone.
For example, the human breast, bone seeking, cancer cell line MDA-
MB-231/B02 secreted cathepsin K and treatment of these cells with
a cathepsin K antagonist can inhibit tumor invasion [155]. Due to its
selectivity, odanacatib is the only cathepsin K inhibitor in clinical
development. A phase II controlled study on women with breast
cancer and established bone metastasis, randomized to receive
daily administration of odanacatib or a single dose of zoledronic
acid, showed reduced bone remodeling markers (urinary NTx) after
4 weeks treatment, demonstrating that odanacatib is as effective as
zoledronate to reduce bone resorption markers [156].
Receptor Activator of Nuclear Factor-B Ligand (RANKL), the
Receptor Activator of Nuclear Factor-B (RANK) and the decoy
receptor osteoprotegerin (OPG) are members of the TNF and
TNF-receptor superfamily, which are able to induce proliferation,
differentiation, activation and apoptosis of osteoclastic cells. Bone
remodeling is mediated by the interaction of RANKL expressed
on the osteoblasts, RANK expressed on the osteoclast surface and
OPG which prevents osteoclast activation [157]. Murine models
have shown that RANKL is able to act as chemoattractant and as a
pro-migratory factor in RANK-expressing breast and prostate can-
cer cell lines and that RANKL inhibition is able to reduce bone
lesions and tumor burden in a melanoma model of bone metasta-
sis [158]. It has also been demonstrated that RANK primary tumor
expression levels correlate with the occurrence of bone metastases
and that RANK-expressing cancer could be found in up to 80% of
bone metastases originated from solid tumor [159,160], suggesting
that RANK enables cancer cells to migrate to bone where RANKL
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s abundantly expressed by osteoblasts. Some tumor cells may
irectly express RANKL, whereas others further enhance RANKL
xpression by cell-to-cell contact of tumor cells with osteoblas-
ic cells. This leads cancer cells to enter a vicious cycle where
hey stimulate osteoclasts that express RANK. Bone degradation
y osteoclasts creates further space for expansive tumor growth
ithin the bone microenvironment which releases a variety of
rowth factors and cytokines stored in the bone matrix that fur-
her boost the proliferation of cancer cells [161]. Recently, it has
een shown that DCs also express RANK, and therefore can be stim-
lated by RANKL, responding by upregulation of co-stimulatory
olecules CD86, CD205 and cytokines such as TNF-, IL-6, and IL-
0 leading to Tregs lymphocyte expansion and subsequent local
nd systemic immunosuppression [162]. Together, these result in
nhanced bone resorption, tumor invasiveness and evasion of the
mmune system by cancer cells. Denosumab (AMG 162) is a noncy-
otoxic IgG2 monoclonal antibody with an extremely high afﬁnity
or human RANKL. It was developed to treat patients with skele-
al pathologies mediated by osteoclasts, such as bone metastasis,
nd cancer treatment-induced bone loss (CTIBL). Three large phase
II randomized clinical trials were carried out in order to assess
he efﬁcacy of denosumab. In breast cancer bone metastatic cancer
atients, denosumab was  shown to be superior to zoledronic acid in
elaying the time-to-ﬁrst and time-to-ﬁrst-and-subsequent skele-
al related event (SRE) by 18% and 23%, respectively [163]. Moreover
n castration resistant prostate cancer patients who  suffered from
one metastasis, denosumab treatment signiﬁcantly prolonged the
edian time to ﬁrst on-study SRE (21 months) compared with zole-
ronic acid (17 months) (p = 0.008) [164]. In a third trial, a total of
776 patients with osteolysis due to myeloma and solid malignan-
ies other than breast and prostate cancer were enrolled showing
 median time to ﬁrst on study SRE of 21 months in the denosumab
roup compared to 16 months in the group receiving zoledronic
cid, and demonstrating a non-inferiority (p = 0.0007) but neither
 superiority for denosumab over zoledronic acid after adjustment
or multiple comparison (p = 0.06) nor an advantage in overall sur-
ival [165]. Finally, in a recent phase III trial conducted in men  with
on-metastatic castration-resistant prostate cancer with a high risk
f developing bone metastasis (NCT00286091), denosumab signif-
cantly prolonged bone-metastasis-free survival by a median of
 months compared to placebo (p = 0.028), potentially conﬁrming
he role of RANK\RANKL in mediating cancer cell homing in to the
one [166].
The proto-oncogene Src (encoded by the c-src gene) is a non-
eceptor, membrane-associated tyrosine kinase that belongs to
rc family kinases modulating key physiological and pathological
rocesses such as cell proliferation, migration and the propensity
f cancer cells to metastasize to the bone [167]. Moreover, Src
oordinates both osteoclast and osteoblast activities; it positively
egulates osteoclast survival and resorbing activity. Conversely,
rc may  negatively regulate osteoblast maturation through inhi-
ition of runt-related transcription factor 2 (Runx2) regulated
enes [168]. Thus, Src kinase is essential for osteoclast activation
nd osteoblast inhibition. Saracatinib is an orally active small-
olecular-weight inhibitor of c-Src and breakpoint cluster region
 c-abl oncogene 1, non-receptor tyrosine kinase (BCR-Abl) able to
nhibit androgen-dependent and androgen-independent prostate
ancer cell proliferation, in vitro migration and in vivo tumor growth
169,170]. Saracatinib also inhibited human osteoclast differenti-
tion and osteoclast-mediated bone resorption in vitro [171]. In
 phase II trial of saracatinib in patients with advanced CRPC,
reatment was  well tolerated and ﬁve patients displayed a slight
eduction in prostate speciﬁc antigen (PSA) levels. Two  phase II
tudies currently ongoing will compare the efﬁcacy of saracatinib
r zoledronic acid plus standard of care on bone turnover in patients
ith bone metastatic breast or prostate cancer (NCT00558272) Biology 35 (2015) S244–S275 S255
and patients with metastatic hormone receptor-negative or locally
advanced unresectable breast cancer (NCT00559507).
Tumor cells not only stimulate osteoclast activity, but also
inhibit osteoblast activity. Inhibition of osteoblast activity has been
linked to the production by the tumor cells of a soluble protein,
namely Dickkopf-1 (DKK-1). DKK-1 protein was  initially discov-
ered as a protein secreted by tumor plasma cells in patients with
multiple myeloma, but is also produced by tumor cells that induce
osteolytic lesions in vivo. DKK-1 inhibits osteoblast activity by
blocking the action of Wnt  proteins on osteoblasts [145]. Wnt
signaling in osteoblasts upregulates OPG expression and down-
regulates RANKL expression [172], suggesting a mechanism by
which Wnt  signaling in osteoblasts indirectly regulates osteo-
clastogenesis. Data from several tumor phenotypes suggest that
DKK1 promotes osteolytic metastases, and may  facilitate the con-
version of osteoblastic metastases to an osteolytic phenotype.
In prostate cancer cells, DKK1 was found to block osteoblastic
metastases without affecting tumor growth, while inhibition of
DKK1 in osteolytic prostate cancer cells switched bone metas-
tases from osteolytic to osteoblastic. Anti-DKK-1 therapy on bone
metabolism and tumor growth was  recently experimented in
mice. DKK-1-neutralizing antibodies restored the bone mineral
density (BMD) of the implanted myelomatous bone, increased
the numbers of osteocalcin-expressing osteoblasts and reduced
the number of multinucleated tartrate-resistant acid phosphatase
(TRAP)-expressing osteoclasts. Furthermore, anti-DKK-1-treated
mice showed reduced tumors burden [173]. BHQ880, a fully
human anti-DKK-1 neutralizing antibody, is currently under eval-
uation in phase I and II trials for patients with multiple myeloma
(NCT00741377, NCT01302886 and NCT01337752).
Recent advances show that the adaption of metastatic can-
cer cells to the bone environment and the subsequent crosstalk
between tumors and host tissue underpin their involvement in the
development of skeletal metastasis. The development of therapeu-
tics to interfere with processes involved in cancer cell colonization
and establishment in the bone, as illustrated in this section, is key
in the management of this metastatic disease. Further research to
identify and establish such compounds is vital.
3.2. Metastatic routes
To successfully metastasize from the primary site, cancer cells
need to successfully overcome a number of barriers. Transporta-
tion of cancer cells throughout the body to distant sites will occur
through one or more of several routes, namely vascular, lymphatic
and transcoelomic routes.
3.2.1. Vascular spread
Vascular dissemination is perhaps one of the best studied routes
of cancer spread. Here cancer cells breach the basement mem-
brane and invade nearby blood vessels, either pre-existing or newly
formed (angiogenesis), to gain access to the circulation and are sub-
sequently transported to a distant site. Through either generic or
speciﬁc mechanisms, cancer cells will arrest on the vascular bed
and extravasate through the vessel wall to their secondary location.
How cancer cells manage to evade and survive immunosurveillance
and how angiogenesis can act as target for anticancer treatment
has been covered by another article in the same issue [174]. The
following section will focus the other two  routes.
3.2.2. Lymphatic spread
Lymphatic dissemination of cancer cells involves the transportof the cancer cells through the lymphatic system. Here, cancer cells
invade into the lymphatic system and are transported to regional
and distant lymph nodes and throughout the body to secondary
sites.
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Accurate staging is critical in predicting prognosis and tailo-
ing therapy for almost every type of cancer. In the preface of the
th edition of the American joint committee in cancer (AJCC) can-
er staging manual, the editors state that the anatomic extent of
isease remains the key prognostic factor in most cancers [175].
owever, the current staging system has 2 major limitations.
irst, there are no preoperative investigations that can predict
ymph node involvement with satisfactory accuracy. Similarly,
argeted biopsy (via radiology guidance, endoscopic ultrasound,
tc.) has an acceptable sensitivity (>85%) for accurately diagnosing
ositive regional lymph nodes, but only those which are com-
letely replaced by tumor cells (i.e. metastatic lymph nodes, not
icrometastic disease). Precision in the preoperative detection of
ymph node metastases is of great importance as the trend toward
ndividualized cancer care and minimally invasive surgery gath-
rs momentum. Second, the not infrequent observation of later
umor recurrence in patients who have seemingly had a com-
lete resection of their tumor suggests that clinically undetectable
umor deposits must be present at the time of operation and the
act that lymph nodes are a frequent site of tumor recurrence
ndicates that this compartment must be an important site for
ccult disease. Recent studies indicate that 1–17% of histologi-
ally negative lymph nodes, and 11–50% of pathologically node
egative patients have nodal metastases that were missed by rou-
ine pathologic examination [176,177]. This therefore means that
 patient’s pN designation is often incorrect and results in subopti-
al  treatment decisions. Robust, sensitive immunohistochemical
echniques using antibodies to detect epithelial tumor cells in
ymphatic tissue have been in use since the mid-1990s [178].
t is therefore surprising that no consensus exists regarding the
rognostic signiﬁcance of immunohistochemically identiﬁed iso-
ated tumor cells (ITCs) in many tumor types [179–194]. The main
eason for this is the lack of unequivocal results showing their
rognostic signiﬁcance in various solid tumors. However, many
tudies suffer from small numbers of patients, limited analysis
f existing parafﬁn blocks, and, most importantly, varying deﬁ-
itions for both isolated tumor cells and micrometastases. As per
he 7th edition of the AJCC cancer staging manual, micrometas-
ases are occult metastases greater than 0.2 mm but not greater
han 2.0 mm in size, while ITCs are deﬁned as small clusters of cells
ot greater than 0.2 mm,  or nonconﬂuent or nearly conﬂuent clus-
ers of cells not exceeding 200 cells in a single histologic lymph
ode cross section [175]. In esophageal cancer, it was  found that
he distinction between an isolated tumor cell and a micrometas-
asis was not important [195]. Patients with either of these in
ne or more lymph node(s) had signiﬁcantly reduced overall sur-
ival compared to patients who remained node negative after
erial sections and immunohistochemistry. The importance of iso-
ated tumor cells in lymph nodes has been reported not only in
sophageal cancer [181,184–187,189], but also in several stud-
es of gastric cancer [196,197], melanoma [198], breast cancer
199–202], colorectal cancer [203–205], and non-small-cell lung
ancer [206]. Lymph nodes containing isolated tumor cells should
ot be designated pN0(i+) as per the AJCC’s breast cancer stag-
ng system. Whether these cells represent tumor cells in transit
s uncertain, but they are associated with a worse prognosis com-
ared to more likely true node negative (pN0) patients. It is likely
hat these cells represent microscopic tumor cell dissemination,
ut practical and economic constraints often prevent their routine
etection.
Although we often categorize cancer as either localized or
etastatic, this simplistic thinking might be misleading. Accord-ng to Klein et al. [207], “the true nature of the disease might
e better conceptualized within an evolutionary model, in which
he continuous selection of genetically unstable variant cells and
heir expansion determines disease course and risk of dying from Biology 35 (2015) S244–S275
cancer”. In this model, a dynamic process of mutation, selection,
clonal expansion, and genetic diversiﬁcation occurs at several pri-
mary and secondary sites simultaneously. Disseminated or occult
tumor deposits (OTDs), such as those found in lymph nodes, may
therefore display quite different chromosomal aberrations from the
primary tumor, and require speciﬁc targeting in adjuvant therapy
settings. The sentinel lymph node (SLN) concept, ﬁrst described by
Morton in the early 1990s [208], depicts the preferential drainage of
a primary tumor to a regional lymph node(s). It is the gold standard
in cancer care for patients with breast cancer and melanoma, but
remains controversial in other solid tumors with continued debate
regarding its role, if any, in staging and treatment algorithms [209].
However, there are 2 reasons why all cancers should adopt the SLN
concept. First, SLN biopsy is the only practical method in today’s
economic climate to identify the most important nodes for detailed
histopathological analysis. And second, adoption of this technique
will promote the development of novel sentinel lymph node trac-
ers, which are capable of non-invasive lymph node staging, and
delivery of chemotherapeutic agents to disseminated tumor cells
within the nodes. Many novel nanomaterials have been proposed
in recent years for medical applications [210] and they are rapidly
progressing toward clinical medicine. Nanoparticles (10–30 nm)
with high binding afﬁnity for lymphoid cells are ideal imaging
agents of the SLNs. Working toward this hypothesis, conjugated
anti-CD45 antibodies with gold nanoparticles (18 nm), through an
optimal polyethylene glycol (PEG) coating, have been constructed
and injected into mice [211]. Analysis conﬁrmed rapid uptake
and transport of the nanoparticles in the lymphatics, as well as
signiﬁcant retention in the lymph nodes. Taking this application
one step further, Weissleder et al. [212] have shown that lym-
photrophic superparamagnetic iron oxide nanoparticles, injected
systemically as exogenous contrast, can discriminate healthy versus
tumor-burdened nodes by the degree of accumulation of particles
in the nodes. At present, there are limitations to the accuracy of
this approach, as false negative results may  occur in the case of
lymph nodes less than 5 mm in diameter, and by extension, those
with early micrometastatic disease. An alternative approach, which
may  offer better accuracy when dealing with micrometastatic dis-
ease, is to inject the tracer via the interstitial route rather than
systemically. Recent studies have shown that mammaglobin-A or
carbonic anhydrase speciﬁc mAbs conjugated to near infrared ﬂu-
orescent dyes can detect as few as 1000 cancer cells in the lymph
nodes after interstitial injection [213,214]. Although this tech-
nique is currently limited to animal studies, the application of
this approach to other imaging modalities holds promise for the
future development of reliable, accurate non-invasive lymph node
staging.
If clonal divergence does indeed exist between occult tumor
deposits in lymph nodes and the primary tumor, a logical solu-
tion would be to deliver anticancer drugs directly to lymphatic
tissues, which would optimize response and limit nonspeciﬁc
organ toxicities of systemic chemotherapeutic agents. Carrier sys-
tems for targeted lymphatic delivery include liposome-based,
polymer-based, and immunotherapy-based [215]. Perhaps the
most promising of these are the polymer-based drug delivery sys-
tems as particle size can be carefully standardized to achieve the
desired effect. As an example, Liggins et al. [216] loaded a syn-
thetic polymer microsphere with paclitaxel (PTX), and injected
them via an intraperitoneal route into a rat model with intraperi-
toneal tumor cells. Rats treated with PTX microspheres showed no
evidence of tumors in the peritoneal cavity, while those without,
all died within 4 weeks. With recent advances in nanotech-
nology and a better understanding of the lymphatic anatomy
and function, targeted chemotherapeutic delivery via polymeric
nano-/microparticles may  greatly improve efﬁcacy of anticancer
treatments.
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.2.3. Transcoelomic metastasis
Spreading and formation of metastatic tumors in the body
avities (mostly in peritoneal and pleural cavities) is a common
eature in certain malignant conditions and are broadly referred to
s transcoelomic metastasis. Trancoelomic spread occurs mostly
rom tumors to adjacent tissues/organs. Transcoelomic peritoneal
etastasis arise mostly from pancreatic cancer, colorectal cancer
nd ovarian cancer, followed by gastric cancer and cervical cancer
217]. The mesothelium is the lining of cavities in the body, mainly
he peritoneal cavity, pleural cavity, and pericardiac cavity. The
ain cell type that forms the mesothelium is the mesothelial cells.
alignant transformation of mesothelial cells results in mesothe-
ioma, an aggressive malignant condition against which there is
ittle effective treatment. It has been reported that mesothelial cells
ay  be a privileged site for tumor cells to attach [218]. This was
hought to be due to the layer of hyaluronan, a molecule released
y mesothelial cells and which, together with other proteins, forms
 protective surface on the mesothelium. Peritoneal metastasis
ccurs via one of two main routes: systemic spreading and local
mplantation after invasion of local tissues. Tumors away from the
avities are likely to develop transcoelomic metastasis via the sys-
emic route, for example, peritoneal metastasis from breast cancer
nd lung cancer. Perhaps most peritoneal metastases come from
umors originated from organs adjacent to the peritoneal cavity,
amely tumors from the stomach, colon, pancreas, ovaries, and
ladder. Cancer cells from these tumors invade surrounding tis-
ues, breach the peritoneal lining and spread by way  of seeding
n the peritoneal cavity, although trans-serosal, inter-serosal and
ub-serosal spread can also be seen. It is clear that in most forms of
eritoneal spreading, tumor-mesothelial interactions are an essen-
ial step in establishing a metastatic tumor in the cavity.
When tumor cells disseminate through and develop a metastatic
esion in the pleural or peritoneal cavity, the cancer cells need
o adapt themselves to the environment and interact with the
esothelial cells. Certain tumors have a far higher incidence of
eveloping peritoneal metastasis. Of course, peritoneal metasta-
is does not occur alone, and can be seen as locoregional issues of
 wider spread of cancer cells. For example, 70% of ovarian can-
ers which have local regional lymphatic metastases also have
eritoneal metastases [219]. Similarly, 50% of patients with gas-
ric cancer which has invaded serosa have peritoneal metastasis
220,221] and the majority of patients with pancreatic cancer have
eritoneal metastasis [222]. Sadly, patients with wide spread perit-
neal metastasis survive no longer than 6 months [223]. Treatment
ptions for peritoneal metastasis are rather limited. Management
nvolves surgical procedure to remove the primary tumor. How-
ver, this has little impact on established peritoneal metastasis.
n the case of systemic metastasis, systemic chemotherapy and
ntraperitoneal chemotherapy have been attempted to treat the
rimary cancer and peritoneal metastasis with limited beneﬁt.
anagement of peritoneal metastasis also involves prevention
nd early intervention. A critical opportunity is during the surgi-
al debulking of the primary tumor, a key procedure. However,
his procedure may  also introduce tumor cells into the periton-
al cavity, although this has been a consequence that surgeons
ave tried to avoid. In addition, peritoneal metastases or tumor cell
eeding are likely to exist at the time of operation. Surgery itself
resents an excellent opportunity to prevent peritoneal metasta-
is and to act early on the metastasis before it becomes full scale
arcinomatosis. Yet, there are very few options for this interven-
ion. Apart from techniques to prevent artiﬁcial seeding, during
urgery (for example the use of padding/isolation materials to
void contact between tumor and surrounding tissues), a widely
racticed approach is peritoneal washing/irrigation following the
urgical procedure with the aim to remove any debris and pos-
ibly existing tumor cells. This is hardly a satisfactory solution, Biology 35 (2015) S244–S275 S257
and further research is essential in order to develop alterna-
tives.
The contact of cancer cells to mesothelial cells is followed con-
sequently by adhesion, invasion and growth of tumor cells at such
a new site. The exact role of mesothelial cells in tumor cell adhe-
sion and growth is unclear. Many studies have demonstrated that
traumatized mesothelial surfaces are privileged sites for tumor
cell adhesion possibly due to the binding of tumor cells to the
hyaluronan coat of mesothelial cells [218], upregulation of adhe-
sion molecules on mesothelial cells in response to inﬂammatory
mediators and exposure of underlying ECM. However, hyaluronan
in conditioned medium from cultured mesothelial cells prevented
tumor cell attachment to mesothelial cells, possibly by binding to
CD44 molecules on the tumor cells and preventing their interaction
with hyaluronan on the mesothelial cell surface [224]. On the other
hand, factors released from tumor cells or adjacent stroma may
also provide a favorable environment for the interaction between
cancer cells and mesothelial cells. For example, IL-1 or TGF-1
from cancer cells can act on the mesothelial cells and/or adjacent
stroma to promote peritoneal dissemination [225,226]. Further
investigation into this particular interaction will shed light on the
mechanism(s) of cancer cell dissemination in pleural and peritoneal
cavities, and may  also provide novel therapeutic opportunities.
4. Therapeutic approach to cancer metastasis
4.1. Natural products with antimetastatic properties
To date, surgery remains the primary cancer treatment option
for patients who  are deemed curative at diagnosis. Existing surgi-
cal procedures are successful in removing the majority of tumors,
however, cancer cells that were missed during surgical removal or
cells that had already migrated out of the primary tumor sites are
important sources for metastasis. The migrated cells later impair
the function at the newly metastasized organ sites. Eventually, the
functional impairment at metastatic sites results in cancer related
mortality [227].
Tremendous advancements have been made in can-
cer screening, early diagnosis and development of novel
chemo(radio)therapy regimens. However, little progress has
been made in cancer prevention or containment of primary tumors
from metastasizing. Therefore, there is a need for a multipronged
approach to prevent the primary tumor from spreading. Two
essential properties of new anticancer drugs are to stop tumor
growth as well as inhibit metastasis. Historically, chemotherapy
drugs were developed to manage primary tumors. We  have
advanced from using single drugs to combination chemotherapy
regimens. In the past decade, several new agents have been
added to the chemotherapy arsenal. These new drugs target
speciﬁc cell signaling pathways. Some of the new targeted agents
include monoclonal antibodies and kinase inhibitors. However,
these new agents are not effective by themselves, but only in
combination with other antimetabolite drugs like 5-ﬂuorouracil.
This highlights the need for more drugs that could target primary
tumors [228].
Only 5% of small molecules (investigational drugs) with medic-
inal properties enter human clinical trials. Several investigational
drugs are taken off clinical studies due to toxicity or lack of efﬁcacy.
Invariably, the trial drugs are seldom used as single agents. Instead,
they are added on to existing drugs. Moreover, clinical trials focus
on reducing primary tumor burden. On the other hand, these inves-must rededicate our efforts to go beyond reducing primary tumor
burden. For example, EMT, while important in development and
wound healing, is detrimental in cancer patients as it is a hallmark
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f metastasizing cancer cells. Thus, focus on how to prevent EMT
n cancer cells represents a key area of research toward treatment
evelopment. A good approach could be to develop a set of mark-
rs affected in EMT. Such a panel could serve as a benchmark for
mall molecular screens to select molecules with anti-EMT prop-
rties. Usually, these small molecules alone are not cytotoxic but
ay  have antimetastatic activity through their interactions with
ey EMT  regulators, etc. The small molecules selected through such
creens may  be combined with the standard of care drugs to beneﬁt
ancer patients.
Many anticancer agents in use were originally developed from
atural products. Plants, fungi and marine organisms are the major
ources for new drug discoveries. About 60–85% of chemother-
py agents in use are natural product derivatives [229]. However,
ot all the bioactive molecules isolated from a natural product are
ntroduced to the clinic because these molecules may  be either toxic
r do not inhibit cancer cell growth in vitro. However, the isolated
mall molecules may  inhibit speciﬁc signaling factors involved in
umor promotion. Current anticancer drug discovery efforts focus
n tumor cell toxicity. Such approaches will miss speciﬁc inhibitory
ctivities of the test compounds. Therefore, we need to system-
tically screen small molecules for their antimetastatic properties
s well. Molecules thus identiﬁed, may  be combined with other
ytotoxic drugs to inhibit metastasis.
Drug discovery from natural products has two important chal-
enges. The ﬁrst is technical. The second, and equally important,
s biodiversity (governmental) regulations. Synergism of multiple
olecules in crude preparations is an important technical obsta-
le. Even when a single active molecule has been identiﬁed, in vitro
ynthesis of natural products has proved difﬁcult. Understand-
bly, environmental concerns and intellectual property (IP) issues
ffect acquiring natural products nationally and internationally.
iewed from a broader perspective, the Biodiversity convention
ules and regulations are essential. Despite these obstacles, the
dentiﬁcation and generation of new therapeutic strategies to tar-
et cancer metastasis has great potential. Research into this area is
ngoing and numerous compounds have demonstrated anticancer
ctivity.
This review outlines and has discussed key factors and pathways
nvolved in the establishment of an invasive cancer cell pheno-
ype and metastatic dissemination. The ability to understand this
rocess fully is an invaluable tool in combating this process. Fur-
hermore, identiﬁcation of suitable, low-toxicity compounds which
nterfere with these processes in cancer cells is paramount in gen-
rating a new generation of cheap, readily available compounds.
deal compounds would have low inherent toxicity with cancer
peciﬁc effects, would have low cost and be readily available, have
ffects across a broad range of cancer types rather than speciﬁc
ubsets and be free of intellectual properties. In respect to this,
his review outlines a number of possible targets that may  repre-
ent key areas to target metastatic spread combined with potential
herapeutic approaches to interfere with such targets (Table 2).
iven the complex nature of cancer which extends beyond just
hat of tissue invasion and metastasis, these target approaches
nd potential strategies have also been explored and their efﬁcacy
nvestigated in the key hallmark areas of cancer development and
rogression (outlined in the other articles of this journal edition)
o highlight potential overlaps and further illustrate how these tar-
ets (Table 2) and approaches (Table 3) may  have beneﬁcial holistic
pproaches to cancer. Together these tables summarize key data
cross the literature. This cross-validation is a very important exer-
ise for cross-target and cross dicipline veriﬁcation. It provides
seful information as to whether these approaches and targets have
omplementary or contrary interactions with the other hallmark
reas and, thus, their likelihood of resulting in pro-carcinogenic or
umor-stimulating effects. Biology 35 (2015) S244–S275
4.1.1. Silibinin
One such example is seen in the antimetastic properties of
silibinin, a plant derived anticancer agent. Silibinin is a mixture
of two ﬂavonoids, silibinin A and silibinin B. It is derived from
the milk thistle plant Silybum marianum.  This plant is known for
its hepatoprotective properties. In vitro and in vivo, silibinin is
demonstrated to inhibit cancer cell migration, invasion and metas-
tasis [230]. Tumor necrosis factor related apoptosis inducing ligand
(TRAIL/Apo2L) is an important mediator of intrinsic apoptotic path-
way. However, some tumors fail to respond to TRAIL mediated cell
death signals. Silibinin induces apoptosis in TRAIL-resistant tumor
cells by inducing the caspase cascade [231,232]. Youseﬁ et al. [233]
demonstrated that silibinin inhibited the growth of neuroblastoma
cell line SK-N-MC by downregulating Akt-mediated NF-B1. Silib-
inin is shown to inhibit metastasis by inhibiting the expression of
mRNA levels of GDP dissociation inhibitor (D4-GDI) and cell divi-
sion cycle 42 (Cdc42) in the highly metastatic breast cancer cell line,
MDA-MB-231 and protein levels of CD31, nestin, VEGF, VEGFR1,
VEGFR2, phospho-Akt and hypoxia-inducible factor-1 (HIF-1),
the signaling molecules involved in neovascularization [234].
4.1.2. Yangzheng Xiaoji
Traditional chinese medicines (TCMs) represent another source
of potential antimetastatic agents. Cancer cell adhesion and inva-
sion are key traits in the metastatic cascade. While relatively few
TCMs have been reported to inﬂuence these steps, the formulation
‘Yangzheng Xiaoji’ (YZX) has demonstrated an efﬁcacy in inhibi-
ting cancer cell adhesion, migration and angiogenesis in vitro and
in vivo [235–237]. YZX capsules consist of 16 herbs. An YZX extract,
DME25, did not show a signiﬁcant effect on the growth of cancer
cells though it markedly suppressed cell adhesion and migration.
It has been demonstrated that YZX inhibited the cell adhesion of
gastric cancer cells (HGC27) in a concentration dependent manner,
colorectal cancer cells (HRT18), breast cancer cells (MCF7), lung
cancer cells (A549) and osteosarcoma cells (MG-63) and the migra-
tion of lung cancer cells and colorectal cancer cells. In addition,
it was  veriﬁed that the inhibitory effect of YZX on the adhesion
of cancer cells is related with PI3K signal pathway. Wortmannin,
an inhibitor of PI3K activity, can suppress PI3K/AKT signaling and
consequently reduce adhesiveness of cancer cells. DME25 which
also targets the AKT pathway can enhance such inhibitory effect.
The inﬂuence of DME25 on the PI3K pathway may not depend
on only one signal pathway, namely the AKT pathway [235,237].
Another study has demonstrated that YZX can suppress the forma-
tion of canaliculus of vascular endothelial cells, and indicated that
cell matrix adhesion and migration could be inhibited in a concen-
tration dependent manner [236]. Cell adhesion and migration are
critical during angiogenesis, particularly canaliculus formation by
vascular endothelial cells when they adhere to the cell matrix and
subsequently migrate in the ECM.
The FAK signaling pathway is a key pathway involved in
cell–matrix adhesion [238–240]. DME25 has been reported to have
an inhibitory effect on the phosphorylation of the FAK pathway,
while treatment with a FAK inhibitor signiﬁcantly enhanced the
effect of DME25 on the FAK pathway [241]. YZX has also demon-
strated the ability to not only inhibit the growth of colorectal cancer
cells and lung cancer cells but also to suppress the formation of
mouse peritoneal tumor nodules in vivo. The signiﬁcant inhibition
of tumor growth could be observed in both oral administration and
intraperitoneal injection. FAK and phospho- FAK immunoﬂuores-
cent staining indicated that YZX lowered the expression of FAK and
could inhibit the activation of FAK through treatment with a com-
bination of DME25 and FAK inhibitor. Hence, YZX demonstrates
potential as a novel antimetastatic agent, targeting key traits in
the metastatic cascade and demonstrating efﬁcacy using in vivo
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Table 2
Priority targets for tissue invasion and metastasis.
Priority targets for
tissue invasion and
metastasis other
cancer hallmarks
Upregulation of
E-cadherin
Promotion of
formation of
tight junctions
(claudins, etc.)
Suppression of
synthesis,
secretion and/or
activity of the
urokinase
plasminogen
activator (uPA)
Inhibition of
PI3K/AKT
signaling
Inhibition of
FAK signaling
Inhibition of
AP-1 activity
Inhibition of
NF-B
Suppression of
synthesis,
secretion
and/or activity
of MMP-9
expression
Inactivation of
-catenin/ZEB1
signaling
Inhibition of
TGF-
signaling
Genomic instability +
[299]
0 0 +
[300]
0 0 +
[301–303]
0 0 0
Sustained  proliferative
signaling
+/−
[304,305]
+
[306,307]
+
[308,309]
+
[310,311]
+
[311,312]
+
[313]
+
[314–316]
+
[317,318]
+
[319]
+
[278,320]
Tumor-promoting
inﬂammation
+/−
[321,322]
+
[323,324]
0 +
[325–327]
+
[328,329]
+
[330,331]
+
[332,333]
+
[334]
+
[335]
+
[336,337]
Evasion of anti-growth
signaling
+/−
[304,338–340]
+
[341,342]
0 +
[343]
+
[344,345]
+
[346,347]
0 +
[348,349]
+
[350]
+/−
[255,351–353]
Resistance to apoptosis +
[354]
+
[355]
+
[356]
+
[357]
+
[358]
+
[359]
+
[360]
+
[361]
+
[362]
+
[262]
Replicative
immortality
0 0 −
[363]
+/−
[364–366]
+
[367]
−
[368]
+/−
[369–371]
+
[367]
0 −
[372,373]
Dysregulated
metabolism
+
[374,375]
0 +
[376]
+
[377]
+
[378]
0 +
[379]
0 0 +
[380]
Immune system
evasion
0 0 +
[381]
+/−
[382,383]
0 0 +
[384]
0 0 +
[385]
Angiogenesis −
[386]
−
[387]
+
[388]
+
[389]
+
[390,391]
+
[392–394]
+/−
[395,396]
+
[397]
+
[398]
+/−
[399]
Tumor
microenvironment
+/−
[400,401]
+
[402]
+
[309]
+
[403]
+
[404,405]
+
[406,407]
+
[408]
+/−
[409,410]
+
[319]
+
[411]
Key targets identiﬁed in tissue invasion and metastasis were also examined in the other hallmark areas of cancer. Targets relevant to other hallmarks are listed as complementary (+) if they display anti-carcinogenic effects,
contrary  (−) if they display pro-carcinogenic effects or controversial (+/−) if they display both anti- and pro-carcinogenic affects, or identiﬁed as having no known relationship (0).
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metastasis models. Further research into this compound and other
TCM as viable, new antimetastatic agents is fully warranted.
4.1.3. Medicinal mushrooms as a source of anticancer agents
The beneﬁcial anticancer properties of a variety of food and
natural compounds have been known for millennia. Isolation and
characterization of speciﬁc compounds combined with advances
in new molecular biology techniques have helped to identify new
speciﬁc targets. For example, certain phytochemicals including
alkaloids, carotenoids, and ﬂavonoids demonstrated anti-invasive,
antimetastatic and antiangiogenic activities in cell culture and
animal experiments (reviewed in [242,243]). In addition to the
typical dietary phytochemicals from soy, green tea, berries, spices
and other dietary plants, edible and medicinal mushrooms con-
tain a variety of speciﬁc compounds which can target signaling
molecules/pathways involved in cancer progression, metastasis
and angiogenesis. Different mushroom components also modulate
immune system resulting in the secretion of a variety of cytokines
and stimulation of natural killer cells which are responsible for their
anticancer activities. Table 4 lists a number of mushroom compo-
nents that have direct targets in cancer cells. We should redouble
our efforts on these natural products for their antimetastatic prop-
erties.
4.2. Targeting TGF-  ˇ in cancer using small molecule inhibitors
TGF-, discovered in the early 1980s, has been recognized as a
pivotal cytokine involved in a broad range of physiological pro-
cesses. It is also well known for playing a crucial role in tumor
cell behavior, regulating cell growth/proliferation, angiogenesis,
EMT, tumor cell migration, invasion and metastasis. Studies have
described dual functions for TGF- in tumorigenesis, that of a
tumor suppressor in normal cells and in cancer cells in early
stages of tumor development and that of a tumor promoter in
late stages of tumor progression, enhancing immune suppression,
angiogenesis, migration, invasion and metastatic dissemination
[244–246]. In humans, three isoforms have been identiﬁed in
the TGF- superfamily (TGF-1–3), all of which signal through
a heterotetrameric complex consisting of two transmembrane
receptor serine/threonine kinases, one of type I (TGF-R1 or activin
receptor-like kinase 5, ALK5) and one of type II (TRII) (Fig. 3).
Signal transduction is initiated by binding of TGF- to TRII result-
ing in the recruitment of ALK5 into the complex and its activation
through phosphorylation in the GS region (glycine/serine rich
domain). This triggers the phosphorylation of intracellular media-
tors, the receptor-regulated Smads (R-Smads) Smad2 and Smad3 by
ALK5. Phosphorylated Smad2 or Smad3 then complex with Smad4
and the resulting hetero-Smad complex is translocated to the
nucleus to activate the transcription of various TGF--responsive
genes [247] (Fig. 3). Given the involvement of TGF- in tumori-
genesis and in particular tumor promotion, the targeting of the
TGF- signaling pathway for therapeutic purposes appeared to be a
promising strategy. Up to now, several inhibitors have entered clin-
ical trials, from phase I to III. A comprehensive list of therapeutic
TGF- signaling inhibitors used in pre-clinical and clinical studies
has recently been published [248]. Based on the TGF- signaling
pathway, four major strategies of interfering with TGF- expres-
sion, function, or signaling have emerged.
The ﬁrst and clinically most advanced strategy relies on direct
or indirect inhibition of TGF-1 or TGF-2 secretion includ-
ing blocking the generation of the TGF- ligand using antisense
oligonucleotides to TGF- mRNA. Silencing oligonucleotides have
been clinically validated with the anti-TGF-2-speciﬁc phos-
phorothioate antisense oligonucleotide AP12009 (trabedersen,
Antisense Pharma) [249] demonstrating a signiﬁcant increase in
survival rate for patients with recurrent refractory high-grade
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Table  4
Effective anticancer agents present in medical mushroom.
Mushroom Cell line(s) Compound(s) Biological effects Molecular targets Ref
Agaricus blazei HRA (ovarian)
LL3 (lung)
-(1–6)-d-glucan Inhibition of cell proliferation,
induction of apoptosis,
suppression of metastasis
↑ p38 MAPK, caspase-9
↓  uPA
[418]
S180 (sarcoma)
BEL-7402 (liver)
B16 (melanoma)
Linear
-(1–3)-d-glucan
Inhibition of tumor growth,
angiogenesis
Inhibition of invasion through
matrigel, regression of
metastatic tumors
↓ VEGF
↓  MMP-9, ↑ nm23-H1
[491]
[492]
U937 (leukemia) Agaritine Induction of apoptosis ↑ caspase-3, -9 [458]
Hep3B (liver) Blazeispirol Induction of apoptosis ↑ caspase-3, -9, ↓ Bcl-2, ↓
Bcl-xL
[493]
Albatrellus conﬂuens CNA1 (nasopharyngeal)
HeLa (cervix)
MCF-7 (breast)
SW480 (colon)
K567 (leukemia)
Raji, B95-8 (lymphoblast)
U2OS, MG63 (osteosarcoma)
CNE1 (nasopharyngeal)
Grifolin Induction of apoptosis
Induction of apoptosis
Cell cycle arrest at G1
↑ caspase-3, -8, -9, ↓ Bcl-2
↑ PARP, caspase-3, -9,↓ Akt,
FOXO, GSK3
↓ ERK1/2, ERK5, ↑ p19
↑  DAPK1, p53
↑  p21
[494]
[419]
[447]
[495]
[496]
Antrodia camphorata HT-29, HCT116, SW-480
(colon) MDA-MB-231 (breast)
Triterpenes
(zhankuic acids)
Induction of apoptosis ↑ PARP, ↓ Bcl-2, ↓
pro-caspase-3
[497]
Huh7, HepG2, Hep3B (liver)
OEC-M1, OC-2 (oral)
Methyl antcinate A Induction of apoptosis
Induction of apoptosis
↑ Bax, Bak, PUMA, ↓ Bcl-2,
Bcl-xl,
↑ caspase-2, -3, -9
↑ Bax, PARP, caspase-3, ↓ Bcl-2,
Bcl-xl
[498]
[499]
HepG2 (liver) Methylancinate B
Antcin B
Induction of apoptosis,
enhancing oxidative stress
↑ caspase-2, -3, -8, -9, ↑ Fas,
FasL Bax, ↓ Bcl-2, Bcl-xl
[500]
MDA-MB-231 (breast)
H441, H1975 (lung)
Antrocin Induction of apoptosis
Induction of apoptosis
↓ Bcl-2, Bcl-xl, surviving, ↓
mTOR, GSK-3,  NF-B
↓ JAK2, STAT3, mcl-1, ↑
caspase-3
[501]
[502]
A549 (lung) Antroquinol Induction of apoptosis ↓ PI3K, mTOR, Bcl-2, ↑ PARP,
caspase-3
[503]
PANC-1, AsPC-1 (pancreas) Antroquinol Induction of apoptosis,
autophagy, accelerated
senescence
↓ Akt, mTOR, ↑ p21, K-ras [504]
HL-60 (leukemia) Dehydroeburicoic
acid
Induction of apoptosis ↑ PARP, caspase-3, ↓
topoisomerase II
[505]
Cordyceps militaris MDA-MB-231,
MCF-7 (breast)
PC-3 (prostate)
LNCaP (prostate)
SK-N-BE(2)-C (neuroblastoma)
SK-MEL-2 (melanoma)
5637, T-24 (bladder)
Cordycepin Induction of apoptosis,
Induction of autophagy
Induction of apoptosis
Inhibition of cell motility and
invasiveness
Induction of apoptosis
Growth inhibition, cell cycle
arrest at G2/M
Inhibition of TNF--induced
migration and invasion
↑ caspase-3, -9, Bax
↑ LC3
↑  caspase-3, -9, Bax/Bc-2, ↓ IAP
↓ MMP-2,-9, ↑ TIMP-1,-2, ↓
PI3K/AKT
↑  caspase-3, PARP
↑ p21, p-JNK
↓ MMP-9, NF-B, AP-1
[506]
[507]
[508]
[509]
[422]
[510]
Cordyceps
sphecocephala
HepG2 (liver)
SK-N-SH (neuroblastoma)
Polysaccharide
peptide
Induction of apoptosis ↑ caspase-3, Bax, ↓ Bcl-2 [511]
Cordyceps sinensis B16 (melanoma) Exopolysaccharide Inhibition of tumor growth in
lungs and liver
↓ c-myc, c-fos, VEGF [512]
HepG2 (liver) Ergone Induction of apoptosis, cell
cycle arrest at G2/M
↑ caspase-3,-8, 9, PARP, ↑ Bax,
↓  Bcl-2
[513]
CGTH W-2  (thyroid) Cordycepin Induction of apoptosis ↑ caspase-7, PARP [514]
Ganoderma lucidum THP-1 (leukemia) Polysaccharides Induction of apoptosis ↑ DR3, DR4/5
↑ caspase-3, -7, -8, -9, p53
[515]
[516]
S180 (sarcoma) Polysaccharides Cell cycle arrest at G2/M,
inhibition of tumor growth
↑ Bax, ↓ Bcl-2 [517]
NTUB1, N/P(14)
N/As (0.5) (urothelial)
Polysaccharides Enhancing apoptosis in therapy
resistant cancer cells
↑ Fas, caspase-3, -9, ↑ Bax, Bad,
↓  Bcl-2, Bcl-xL
[518]
HUVECs (endothelial) Polysaccharide-
peptide
Induction of apoptosis,
inhibition of angiogenesis
↓ Bcl-2/Bax, VEGF [519]
SGC-7901 (gastric) Protein Lz-8 Induction of autophagy ↑ ATF4, CHOP [473]
THP-1 (leukemia) Lipids Induction of apoptosis ↓AKT, Erk1/2, ↑ JNK1/2,
caspase-3, -8, -9
[520]
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Table 4 (Continued)
Mushroom Cell line(s) Compound(s) Biological effects Molecular targets Ref
Huh-7 (liver)
HT-29 (colon)
Triterpenes Inhibition of growth, cell cycle
arrest at G2
Induction of autophagy
↓ PKC, ↑ p38MAPK, ↑ JNK
↑ Beclin-1, LC3, ↓ p38 MAPK
[521]
[522]
HepG2 (liver) Ganoderic acid A Sensitizing to
cisplatin-induced apoptosis
↓ STAT3, JAK1, JAK2 [523]
MDA-MB-231 (breast) Ganoderic acid A, H Inhibition of cell growth, cell
adhesion, migration and
invasion
↓ CDK4, uPA, ↓ NF-B, AP-1 [426]
MCF-7 (breast) Ganoderic acid DM Inhibition of cell growth,
induction of apoptosis
↓ CDK2, CDK6, c-Myc, ↓ cyclin
D1, ↑ PARP
[452]
95-D (lung) Ganoderic acid Me Inhibition of cell adhesion and
migration
↓ MMP-2/9 [524]
HeLa (cervix) Ganoderic acid Mf,
S
Induction of apoptosis ↑ caspase-3,-9, Bax/Bcl-2 [525]
HCT-116 (colon)
95-D (lung)
Ganoderic acid T Inhibition of cell adhesion and
migration
Induction of apoptosis
↓ uPA, MMP-2/9, NF-B
↑  p53, Bax
[526]
[527]
LNCaP (prostate) Ganoderol B Binding to androgen receptor ↓ 5-reductase [528]
MDA-MB-231 (breast)
HCT-116, HT-29 (colon)
Ganodermanontriol Inhibition of cell growth, cell
adhesion, migration and
invasion
Inhibition of tumor growth
↓ CDC20, uPA, uPAR
↓  cyclin D1, -catenin
[308]
[529]
HepG2 (liver) Lucidenic acid B Inhibition of invasion ↓ MMP-9, NF-B, AP-1 [530]
Grifola frondosa SGC-7901 (gastric) Polysaccharide-
peptide
Cell cycle arrest at G2/M,
induction of apoptosis
↑ caspase-3, Bax, ↓ Bcl-2 [531]
MCF-7 (breast) -Glucan Induction of apoptosis ↑ BAK-1 [532]
PC-3 (prostate) -Glucan Cell cycle arrest at G1,
induction of apoptosis
↓ CDK2,4,6, cyclin D1, E [533]
Lentinus edodes HepG2 (liver) Mycelia Induction of apoptosis ↑ caspase-3,-8 [534]
KB, HSC3 (oral squamous) -d-glucan
(lentinan)
Inhibition of growth, induction
of apoptosis
↓ TS, DPD, ↑ OPRT [535]
Pleurotus abalones MCF-7 (breast) Polysaccharides Inhibition of proliferation, cell
cycle arrest at S, induction of
apoptosis
↑ caspase-3,-9, PARP, ↑
Bax/Bcl-2, p53
[536]
Pleurotus ostreatus HT-29 (colon) -Glucan Inhibition of cell proliferation,
induction of apoptosis
↑ Bax [537]
Pleurotus
pulmonarius
Normal colon Glucans Inhibition of colon
carcinogenesis in mice
↑ Bax, ↓ Bcl-2, NF-B [538]
Huh7, Hep3B (liver) Polysaccharide-
protein
complex
Inhibition of proliferation and
invasion, inhibition of tumor
growth
↓ PI3K/AKT, VEGF [539]
Poria cocos MCF-7 (breast) -Glucan Inhibition of cell proliferation,
cell cycle arrest at G1,
induction of apoptosis
↓ cyclin D1, cyclin E, ↑
Bax/Bcl-2
[540]
BxPc-3 (pancreas) Triterpenes
Pachymic acid
Inhibition of cell proliferation
and invasion
cell cycle arrest at G0/G1
↓ KRAS, MMP-7 [427]
MDA-MB-231, MCF-7 (breast)
DU145 (prostate)
Pachymic acid Inhibition of cell invasiveness
Inhibition of cell proliferation,
induction of apoptosis
↓ MMP-9, NF-B
↑  p21, ↓ Bad, ↑ Bcl-2, ↑
caspase-3,-9
[488]
[462]
NUGC-3 (gastric) Dehydroebryconic
acid
Inhibition of cell proliferation,
cell cycle arrest at G1
↓ DNA topoisomerase II [541]
A549 (lung) Polyporenic acid C Inhibition of cell proliferation,
induction of apoptosis
↓ PI3K/AKT, ↑ p53, ↑ caspase-8 [542]
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lioma compared to standard chemotherapy in phase IIb clini-
al trials [250]. AP12009 is currently undergoing phase III clinical
rials for patients with anaplastic astrocytoma and phases I/II clin-
cal trials for patients with pancreatic neoplasms, melanoma, and
olorectal neoplasms. AP11014, another oligonucleotide from Anti-
ense Pharma targeting TGF-1, is also under investigation at an
dvanced preclinical stage.
The second strategy relies on inhibition of TGF- receptor bind-
ng, including the use of monoclonal antibodies to block speciﬁc
GF- isoforms and thus receptor-ligand interactions. This strat-
gy comprises three compound groups: highly speciﬁc anti-ligand
onoclonal antibodies, soluble TGF- receptors (fusion constructsuction of apoptosis
uction of apoptosis
↑ caspase-3,-8,-9, Bax/Bcl-2
↑ AIF, Bax/Bcl-2
[543]
like soluble TR2:Fc fusion proteins) and synthetic peptides. The
three most advanced antibodies are GC-1008, CAT-152, CAT-192.
The synthetic peptides, P17, P144, have also been used to mod-
ulate the TGF- pathway, of which the most advanced is P144
(DigNA Biotech). P144 blocks the binding of TGF-1 to ALK5 and
TRII. Systemic treatment of mice with either P17 or P144 signiﬁ-
cantly reduced tumor burden induced by TGF-1 and in metastatic
nodules consistently reduced mitotic/apoptotic ratio, mesenchy-
mal  traits and angiogenesis induced by TGF-1 [251].
The third strategy is based on inhibition of TGF- receptor acti-
vation and involves small molecules that block the ALK5 kinase
and hence all Smad and non-Smad signaling pathways originating
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Fig. 3. Canonical TGF- Smad signaling pathway from initiation to nucleus. The
active TGF- ligand can bind TRII (or the accessory receptor TRIII, not shown),
which results in bridging of TRI/ALK5 in to the complex, and allows TRII to phos-
phorylate ALK5. Following recruitment to ALK5 (a process that can be facilitated by
auxiliary proteins such as SARA), the R-Smads Smad2 and Smad3 are phosphory-
lated by the ALK5 kinase. These activated R-Smads form a complex with the Co-Smad
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mmad4 and this complex is imported into the nucleus where in association with
nteracting transcription factors and p300/CBP it binds to the Smad binding element
SBE) in target gene promoters to drive transcription from these genes.
rom TRII and ALK5. In contrast to the large molecule strate-
ies highlighted above, small molecules offer the possibility of
ntracellular modulation of the TGF- pathway. The extensive
nowledge of the ALK5-dependent Smad2/Smad3 phosphoryla-
ion pathway has made ALK5 and TRII attractive targets for the
harmaceutical industry and has focused the research toward
he development of small molecules ALK5 inhibitors which act
s competitive inhibitors for the catalytic adenosine triphosphate
ATP)-binding site of the ALK5 kinase. The TGF- signaling pathway
ffers many different avenues for therapeutic intervention such as
he intracellular inhibition of the ALK5 kinase and/or dual inhibitors
f both the ALK5 and TRII kinases with small molecule inhibitors.
n overview on these agents and their pre-clinical and clinical use
as already been given in excellent reviews [248,252–255].
Inhibition of ALK5 kinase with compounds such as SB431542,
Y573636, SD-208, SM16, SX-007, IN-1130 and YR-290 has illus-
rated their anticancer efﬁcacy. Treatment of glioma cultures with
B431542 inhibited proliferation, TGF--mediated morphologic
hanges and cellular motility [256], and attenuated the tumor-
romoting effects of TGF-, including TGF--induced EMT, cell
otility, migration and invasion and VEGF secretion in human can-
er cell lines [257]. LY573636 is currently being assessed in phase I
nd phase II studies of patients with advanced solid tumors (unre-
ectable or metastatic malignant melanoma, metastatic soft tissue
arcoma, metastatic non-small cell lung cancer (NSCLC), and ovar-
an cancer) [258,259]. Another compound, SD-208, inhibits growth
nd invasiveness of murine and human glioma cells in vitro and
n vivo, resulted in increased inﬁltration of the tumor with immune
ffector cells and prolonged survival in mice bearing intracra-
ial SMA-560 gliomas [260]. Treatment of syngeneic R3T or 4T1
umor-bearing mice with orally administered SD-208 inhibited
rimary tumor growth as well as the number and size of metas-
ases and also resulted in a decrease in tumor angiogenesis [261].
n pancreatic adenocarcinoma, SD-208 inhibited TGF--stimulated
nvasion in vitro and reduced primary tumor growth and incidence
f metastasis in an orthotopic xenograft mouse model [262]. In
elanoma cell lines, SD-208 blocked TGF- induction of Smad3
hosphorylation, Smad3/4-speciﬁc transcription, Matrigel base-
ent membrane invasion and expression of TGF- target genes Biology 35 (2015) S244–S275 S263
and also prevented the development of osteolytic bone metas-
tases and signiﬁcantly reduced the size of osteolytic lesions in mice
with established bone metastases [263]. Similarly, SM16 showed
potent activity against established AB12 malignant mesothelioma
tumors using an immune-mediated mechanism and was  found
to signiﬁcantly prevent tumor recurrence after resection of bulky
AB12 malignant mesothelioma tumors [264]. Blockade of TGF-
signal transduction in 4T1 tumor cells by SM16 prevented TGF-
-induced morphological changes and inhibited TGF--induced
invasion in vitro, inhibited Smad2 phosphorylation in cultured 4T1
tumor cells as well as in primary and metastatic 4T1 tumor tissue
and inhibited the growth of primary and metastatic 4T1 tumors
in vivo [265]. The combination of SM16 with anti-OX40 elicited a
potent antitumor effect against established poorly immunogenic,
highly metastatic, TGF--secreting primary 4T1 mammary tumors,
with a 79% reduction in tumor size, a 95% reduction in the num-
ber of metastatic lung nodules, and a cure rate of 38% [266].
SX-007, an orally active, pyridopyrimidine ALK5 kinase inhibitor,
was also evaluated for its therapeutic potential in cell culture
and in the syngeneic, orthotopic glioma model SMA-560, where
it exerted a therapeutic effect by reducing TGF--mediated inva-
sion, reversing immune suppression and improving survival in
this model [267]. The IN-1130 inhibitor has also displayed anti-
tumor effects in mice injected subcutaneously with the murine
prostate cancer cell line Tramp C2. Here the treatment group
demonstrated a dramatic decrease in tumor volume in associa-
tion with an enhanced immune response [268]. YR-290 has also
been shown to inhibit the TGF--mediated downstream signaling
pathway, metastasis-associated genes, and TGF--dependent cell
migration and invasion in breast cancer cells. In tumor metastasis
mouse models, YR-290 almost completely blocked cancer metas-
tasis, reducing lung tumor nodules in comparison with control
animals and signiﬁcantly prolonged the survival of tumor-bearing
mice [268].
Dual inhibitors of the ALK5 and TRII kinases have also been
studied, again demonstrating potential anticancer effects. Exam-
ples of such compounds include LY2157299 and LY2109761.
One compound, LY2157299, that can be orally administered,
has entered phase I trials for advanced/metastatic cancer. Daily
oral administration of LY2157299 was  safe and well tolerated
[269]. In triple negative breast cancer (TNBC) cell lines and
mouse xenografts, the chemotherapeutic drug paclitaxel increased
autocrine TGF- signaling and IL-8 expression and enriched for
CSCs, as indicated by mammosphere formation and CSC mark-
ers. LY2157299 blocked paclitaxel-induced IL-8 transcription and
CSC expansion. Moreover, treatment of TNBC xenografts with
LY2157299 prevented reestablishment of tumors after paclitaxel
treatment. These data suggest that chemotherapy-induced TGF-
 signaling enhances tumor recurrence through IL-8-dependent
expansion of CSCs and that TGF- pathway inhibitors prevent
the development of drug-resistant CSCs and argue for testing a
combination of TGF- inhibitors and anticancer chemotherapy
in patients with TNBC [270]. Similarly LY2109761 has displayed
efﬁcacy as an anticancer agent. LY2109761 decreased liver metas-
tases and prolonged survival in mouse models of colon metastasis
[271] and in decreased metastasis in a mouse model of pancre-
atic cancer model [272]. LY2109761 inhibited TGF--mediated
activation of Smad and non-Smad pathways in CT26 colon ade-
nocarcinoma cells having V-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (K-Ras) mutation and attenuated the oncogenic
effects of TGF- on cell migration, invasion and tumorigenicity
of CT26 cells. These ﬁndings highlight the therapeutic value of
LY2109761 for metastatic colorectal cancer [271]. Both LY2157299
and LY2109761 inhibited TGF--stimulated in vitro migration and
invasiveness of MDA-MB-231 subclones and signiﬁcantly reduced
the metastatic burden to either lungs or bones in vivo. Besides
S ancer Biology 35 (2015) S244–S275
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Table 5
Overview of TGF- signaling inhibitors used in pre-clinical and clinical studies. The
mechanism of action involves (i) direct or indirect inhibition of TGF- secretion, (ii)
inhibition of TGF--T  R binding, (iii) inhibition of TR activation, or (iv) inhibition
of  Smad activation. ASON, antisense oligonucleotide; mAb, monoclonal antibody.
See  text for speciﬁc details.
Target protein Inhibitor (type) Mechanism
TGF-1
TGF-2
TGF-1–3
AP11014 (TGF-1-speciﬁc ASON)
CAT-192/Metelimumab (rec.
human IgG4 anti-TGF-1 mAb)
AP12009,
Lucanix/Belagen-pumatucel-L
(TGF-2-speciﬁc phosphorothioate
ASONs)
CAT-152 (rec. human IgG4
anti-TGF-2 mAb)
GC-1008 (human anti-panTGF-
mAb)
1D11, 2G7 (anti-panTGF- mAbs)
(i)
(ii)
(i)
(ii)
(ii)
(ii)
TRII  Soluble TR2:Fc fusion protein
(soluble TGF- receptors)
LY2109761, LY2157299 (small
molecules)
(ii)
(iii)
TRI/ALK5 A-83-01, Antp-Sm2A, EW-7195,
EW-7203, IN-1130, Ki-26894,
LY2109761, LY2157299,
LY364947/HTS-466284, LY550410,
LY573636, LY580276, NPC30345,
PP1, PP2, SB431542, SB505124,
SD-093, SD-208, SKF104365, SM16,
SM305, SX-007, YR-290 (small
molecules)
(iii)
TRIII/Betaglycan P17, P144 (synthetic peptides) (iii)
Smad2 Peptides mimicking Smad2 (Smad (iv)264 W.G. Jiang et al. / Seminars in C
nhibiting metastasis in a tumor cell autonomous manner, the
GF- antagonists inhibited angiogenesis associated with lung
etastases and osteoclast number and activity associated with lytic
one metastases [273]. A large series of studies with LY2157299
nd LY2109761 have been completed in the hepatocellular carci-
oma (HCC) model. LY2157299 and LY2109761 inhibited HCC cell
igration on laminin-5, ﬁbronectin, vitronectin, and collagen-I and
nvasion through Matrigel [274] both constitutively invasive and
ith acquired invasive properties [275]. This inhibition is asso-
iated with the decreased phosphorylation of Smad2, FAK and
1-integrin (intracytoplasmic tail), and with increased levels of E-
adherin. Finally, in a xenograft model of HCC, LY2109761 strongly
nhibited tumor growth, intravasation and metastasis [276]. These
tudies support the use of LY2157299 in clinical trials. The anti-
umor activity of LY2109761 was also associated with inhibition
f molecular pathways involved in neo-angiogenesis and tumor
rowth of HCC. This anti-angiogenic effect was more effective than
hat of bevacizumab, which speciﬁcally targets VEGF. LY2109761
locked the paracrine cross-talk between HCC and endothelial cells,
nhibiting blood vessel formation. This effect was  mediated by
mad2/3 and affected the secretion of VEGF. Of note, LY2109761 did
ot show signiﬁcant effects on physiological angiogenesis [277].
Y2109761 also interrupted the cross-talk between cancer cells
nd CAFs, leading to a signiﬁcant reduction of HCC growth and
issemination. Preclinical results also indicate that LY2109761 tar-
ets the cross-talk between HCC and the stroma and provide a
ationale for future clinical trials [278]. Zhang and colleagues [279]
ave reported that LY2109761 inhibited radiation-induced inva-
ion, reduced tumor microvessel density, and attenuated EMT  in
lioblastoma. However, there is also evidence of acquired resis-
ance to LY2109761. Therefore, TGF- inhibitors might be clinically
seful for applications requiring acute administration, but long-
erm patient exposure to such drugs should be undertaken with
aution [280].
Other studies have also shown that the Src family kinase
nhibitors PP1 and PP2 are powerful inhibitors of ALK5. In in vitro
inase assays with recombinant ALK5, PP1 and PP2 displayed an
C50 of 5.0 × 10−08 M and 5.6 × 10−07 M,  respectively, with PP1
eing more potent and PP2 being nearly as potent as SB431542
IC50 of 2.25 × 10−07 M).  PP2, but not PP1 also weakly inhibited
he TRII kinase. In pancreatic carcinoma cells, PP1 and PP2 effec-
ively inhibited TGF-1-induced phosphorylation of Smad2/3 and
38 MAPK, gene expression, and EMT  in vitro [281]. Together, these
ata show that PP1 and PP2 strongly inhibit the ALK5 kinase and
an block TGF-/Smad signaling in a Src-unrelated fashion. Both
gents may  be useful as dual TGF-/Src inhibitors in experimental
herapeutics of late stage metastatic disease.
The fourth strategy is based on inhibition of Smad activation
nd uses pseudo-substrate inhibitors that mimic  Smads and block
ntracellular Smad signal pathways. While research has focused
n recent years on the generation and therapeutic evaluation of
nhibitors targeting the ALK5 ATP-binding site, another approach
o target the kinase on the substrate-binding site has been reported
282]. This novel strategy aims to inhibit signaling by blocking the
ubstrate-binding site of the ALK5 kinase with peptides mimick-
ng Smad2 (Smad pseudo-substrate inhibitors). This new class of
nhibitors acts as “dominant negative inhibitors” which occupy the
mad2-binding pocket and prevent Smad2 phosphorylation, and
ence its activation. This idea should by deﬁnition allow a high
peciﬁcity that some ATP-mimicking inhibitors (such as SB431542)
o not possess. The results have shown that Smad mimetics can
ndeed impede TGF- signaling by blockage in vivo and in vitro of
LK5-dependent phosphorylation of endogenous Smad2, as well
s downstream events such as gene expression. Finally, these
seudo-substrates have shown higher efﬁciency with the ALK5
inase than with other type I receptor kinases of the TGF-/bonepseudo-substrate inhibitors)
Smad3 SIS3 (iv)
morphogenetic protein (BMP) family [282]. The development of
pseudo-substrate inhibitors is a promising approach that may lead
to new therapeutics. It is widely accepted that the Smad pathway
mediates tumor-suppressor functions of TGF-, while the tumor-
promoting effects of TGF- are largely controlled by non-Smad
pathways. Therefore, the use of compounds that selectively inhibit
Smad signaling may  not be as efﬁcient as ALK5 inhibitors unless the
Smad-independent pathways are activated downstream of Smad
signaling. Hence, tumors that harbor a non-functional Smad path-
way, such as tumors with mutations in DPC4 (encoding Smad4),
might not be amenable to treatment with this kind of inhibitors.
The various targets and inhibitors discussed above are summarized
in Table 5.
5. Perspectives
This article has provided a summary of some of the recent
progress in the area of cancer invasion and metastasis. As high-
lighted in this special issue, although progress in this area over the
past two decades has been rapid, when one considers the severity
of cancer metastasis, the damaging impact on patient’s longevity
and quality of life, and the lack of successful treatment regimens to
combat cancer metastasis, these triumphs are far from satisfactory,
as partly echoed in the capstone article. A great deal more invest-
ment and research is required to provide breakthrough treatments,
which will beneﬁt late stage cancer patients. These achievements
can be seen as early ‘sweeteners’ in this fundamental area of can-
cer research; however, currently there are very limited options for
effective intervention of cancer metastasis. Patients suffering with
metastatic disease commonly have a poorer general condition and
health than those at an early stage. Conventional options, such
as chemotherapy and radiotherapy, generate collateral adverse
effects, which are hard to bear for these patients. Development of
ancer
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ew, better tolerated, treatment approaches is essential. It is pleas-
ng to see that anti-angiogeneic therapies, such as those discussed
n an earlier article of this issue [174], have been shown to be effec-
ive while presenting with far fewer adverse effects. Nevertheless
t is disappointing that similar options for anti-metastasis are not
et available.
The other main focus of this current article was  to explore
he opportunities that reside in phytochemicals, conventionally
eported as having some antimetastatic effects, yet with fewer
dverse effects. However, there are signiﬁcant challenges with phy-
ochemicals. First a lack of IP protection; second, insufﬁcient clinical
fﬁcacy data largely due to the lack of IP protection; Third, a lack of
ontinued thorough investigation into their speciﬁc mechanisms of
ction; and ﬁnally, the relatively weaker effect of these novel agents
n comparison with traditional, high toxicity chemotherapeutic
gents. However, these chemicals may  well hold great potential
ithin this fragile group of patients with poor general condition.
Thus, the current article has called for more investment and
esearch into the mechanism(s) of cancer invasion and metasta-
is. At the same time, it is urged that the phytochemical approach
hould be revisited and emphasized. This area of research may  well
resent an attractive option to this large group of patients with late
tage cancers.
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